,terms,label,prediction
0,risk reduction ( nmbr % cl ),arms;measures,measures
1,gemfibrozil,arms;measures,characteristic_level
2,p value,arms;measures,measures
3,placebo,arms;measures,arms
4,p *,arms;measures,characteristic_level
5,stent plus abciximab,arms;measures,arms
6,stent plus placebo,arms;measures,arms
7,balloon angioplasty plus abciximab,arms;measures,arms
8,pt,arms;measures,characteristic_level
9,abciximab,arms;measures,arms
10,no . of patients,arms;measures,characteristic_level
11,irofiban,arms;measures,characteristic_level
12,p - value,arms;measures,measures
13,placebo ( n = nmbr ),arms;measures,arms
14,sr ii b nmbr - cjl nmbr,arms;measures,characteristic_level
15,placebo ( n = nmbr nmbr ),arms;measures,arms
16,aspirin ( asa ) ( » = nmbr nmbr ),arms;measures,characteristic_level
17,odds ratio ( nmbr % ci ),arms;measures,measures
18,ticlopidine ( n = nmbr ),arms;measures,characteristic_level
19,clopidogrel ( n = nmbr ),arms;measures,arms
20,p,arms;measures,characteristic_level
22,warfarin group ( n = nmbr ),arms;measures,arms
23,placebo group ( n = nmbr ),arms;measures,arms
24,hazard ratio ( nmbr % ci ) *,arms;measures;p-interaction,measures
25,placebo group,arms;measures;p-interaction,arms
26,p value for interaction^,arms;measures;p-interaction,measures
27,warfarin group,arms;measures;p-interaction,arms
28,non - calcium antagonist strategy ( ncas ) ( events / n ),arms;measures,characteristic_level
29,rr ( nmbr % cl ),arms;measures,measures
30,calcium antagonist strategy ( cas ) ( events / n ),arms;measures,characteristic_level
32,p ( losartan versus placebo ),arms;measures,arms
33,risk reduction ( % ; nmbr % ci ),arms;measures,measures
34,chf on placebo ( % ),arms;measures,arms
35,chf on losartan ( % ),arms;measures,arms
36,gfr ( ml / min per nmbr . nmbr nr ),arms;measures,characteristic_level
37,esrd on losartan ( % ),arms;measures,arms
38,esrd on placebo ( % ),arms;measures,arms
39,nmbr % ci,arms;measures,measures
40,"placebo ( n = nmbr , nmbr )",arms;measures,arms
41,"beta - carotene ( n = nmbr , nmbr )",arms;measures,characteristic_level
42,rr *,arms;measures,characteristic_level
49,beta - carotene,arms;measures,characteristic_name
50,p interaction,arms;measures,characteristic_name
52,asp,arms;measures,characteristic_level
53,pla,arms;measures,characteristic_level
54,rr ( nmbr % ci ),arms;measures,measures
56,patients with end point,arms;measures,measures
57,pbo,arms;p-interaction,arms
58,p - value * ' ',arms;p-interaction,measures
59,eze nmbr mg,arms;p-interaction,arms
60,placebo ( n = nmbr nmbr ),arms;p-interaction,arms
61,total ( n = nmbr nmbr ),arms;p-interaction,characteristic_level
62,aspirin ( n = nmbr nmbr ),arms;p-interaction,characteristic_level
63,p value,arms;p-interaction,measures
64,nmbr,outcomes;other,characteristic_level
65,prosper,outcomes;other,characteristic_level
66,lipid,outcomes;other,characteristic_name
67,post - cabg,outcomes;other,characteristic_level
68,lips,outcomes;other,characteristic_level
69,alert,outcomes;other,characteristic_level
70,woscops,outcomes;other,characteristic_level
71,total,outcomes;other,characteristic_level
72,gissi prevention nmbr / nmbr - nmbr / nmbr,outcomes;other,characteristic_level
73,allhat - llt,outcomes;other,characteristic_name
74,ascot - lla,outcomes;other,characteristic_level
75,hps,outcomes;other,characteristic_level
76,cards,outcomes;other,characteristic_level
77,care,outcomes;other,arms
78,afcaps /,outcomes;other,characteristic_level
79,baseline history of vascular disease ( % ),characteristic_name;measures,characteristic_name
80,events treatment ( nmbr ),arms;other,characteristic_name
81,( % ) control ( nmbr ),arms;other,arms
82,heterogeneity / trend test,arms;other,characteristic_name
83,rr ( cl ),arms;other,measures
84,events treatment ( nmbr ),arms;measures;other,characteristic_name
85,( % ) control ( nmbr ),arms;measures;other,arms
86,heterogeneity / trend test,arms;measures;other,characteristic_name
87,rr ( cl ),arms;measures;other,measures
88,black,measures;characteristic_level,characteristic_level
89,hispanic,measures;characteristic_level,characteristic_level
90,asian,measures;characteristic_level,characteristic_level
91,white,measures;characteristic_level,characteristic_level
92,pre - specified hr ( nmbr % cl ),arms;measures,measures
93,losartan,arms;measures,arms
94,adjusted hr ( nmbr % cl ),arms;measures,measures
96,no chd simva ( n = nmbr],arms;characteristic_level,characteristic_level
97,no chd eze / simva nmbr = nmbr },arms;characteristic_level,characteristic_level
98,female eze / simva ( „ = nmbr },arms;characteristic_level,characteristic_level
99,caucasian simva ( „ = nmbr },arms;characteristic_level,characteristic_level
100,> nmbr years simva ( „ = nmbr },arms;characteristic_level,characteristic_level
101,< nmbr years simva ( n = nmbr },arms;characteristic_level,characteristic_level
102,eze / simva ( „ = nmbr },arms;characteristic_level,characteristic_level
103,chd simva nmbr = nmbr],arms;characteristic_level,characteristic_level
104,< nmbr mg / dl simva ( n = nmbr],arms;characteristic_level,characteristic_level
105,female simva ( „ = nmbr },arms;characteristic_level,characteristic_level
106,> nmbr years eze / simva ( „ = nmbr },arms;characteristic_level,characteristic_level
107,chd eze / simva ( n = nmbr],arms;characteristic_level,characteristic_level
108,< nmbr mg / dl eze / simva ( n = nmbr },arms;characteristic_level,characteristic_level
109,non - caucasian simva ( „ = nmbr },arms;characteristic_level,characteristic_level
110,> nmbr mg / dl eze / simva nmbr = nmbr },arms;characteristic_level,characteristic_level
111,simva ( „ = nmbr },arms;characteristic_level,characteristic_level
112,male simva ( „ = nmbr },arms;characteristic_level,characteristic_level
113,< nmbr years eze / simva ( n = nmbr },arms;characteristic_level,characteristic_level
114,non - caucasian eze / simva ( „ = nmbr },arms;characteristic_level,characteristic_level
115,caucasian eze / simva ( „ = nmbr },arms;characteristic_level,characteristic_level
116,> nmbr mg / dl simva nmbr = nmbr],arms;characteristic_level,characteristic_level
117,male eze / simva ( „ = nmbr },arms;characteristic_level,characteristic_level
118,nmbr - year rates in placebo groups,measures;p-interaction,arms
119,| interactior nmbr p,measures;p-interaction,characteristic_level
120,number of patients,measures;p-interaction,characteristic_level
121,hr ( nmbr % ci ),measures;p-interaction,measures
122,p value for interaction,measures;p-interaction,measures
123,neither pbo + statin eze + statin,arms;characteristic_level,arms
124,diabetes mellitus,arms;characteristic_level,characteristic_level
125,metabolic syndrome *,arms;characteristic_level,characteristic_name
128,abciximab ( n = nmbr ),arms;measures,arms
132,"infliximab ( combined nmbr mg / kg and nmbr mg / kg ) , n ( % )",arms;measures,characteristic_level
133,"placebo , n ( % )",arms;measures,arms
134,nmbr % ci for difference,arms;measures,measures
136,difference ( % ),arms;measures,measures
137,etoricoxib,arms;measures,arms
138,diclofenac,arms;measures,arms
139,primary angioplasty ( n = nmbr ),arms;measures,characteristic_level
140,post - fibrinolysis angioplasty ( n = nmbr ),arms;measures,characteristic_level
142,aspirin use,characteristic_name;characteristic_level,characteristic_name
143,corticosteroid use,characteristic_name;characteristic_level,characteristic_name
144,hypertension,characteristic_name;characteristic_level,characteristic_level
145,history of upper gastrointestinal event,characteristic_name;characteristic_level,characteristic_name
146,sex ( female ),characteristic_name;characteristic_level,characteristic_name
147,age > nmbr years,characteristic_name;characteristic_level,characteristic_level
148,diabetes,characteristic_name;characteristic_level,characteristic_name
149,established atherosclerotic cardiovascular disease,characteristic_name;characteristic_level,characteristic_name
150,cigarette smoker,characteristic_name;characteristic_level,characteristic_level
151,hazard ratio ( nmbr % ci ),arms;measures,measures
154,hazard ratio ( nmbr % cl ),arms;measures;p-interaction,measures
155,epa ( n = nmbr ),arms;measures;p-interaction,arms
156,control ( n = nmbr ),arms;measures;p-interaction,arms
157,interaction p,arms;measures;p-interaction,characteristic_name
158,"age , median ( iqr ) , y",characteristic_name;characteristic_level,characteristic_level
159,heparin,characteristic_name;characteristic_level,characteristic_level
160,statin,characteristic_name;characteristic_level,characteristic_level
161,prior heart failure,characteristic_name;characteristic_level,characteristic_level
162,female sex,characteristic_name;characteristic_level,characteristic_name
163,estimated creatinine clearance < nmbr rmb ' mint,characteristic_name;characteristic_level,characteristic_name
164,thienopyridine,characteristic_name;characteristic_level,arms
165,prior mi,characteristic_name;characteristic_level,characteristic_level
166,other,characteristic_name;characteristic_level,characteristic_level
167,glycoprotein iib / iiiareceptorinhibitor,characteristic_name;characteristic_level,characteristic_level
168,"body mass index , median ( iqr )",characteristic_name;characteristic_level,characteristic_name
169,hyperlipidemia,characteristic_name;characteristic_level,characteristic_level
170,current smoker,characteristic_name;characteristic_level,characteristic_level
172,coronary angiography during the index hospitalization,characteristic_name;characteristic_level,characteristic_level
173,diabetes mellitus,characteristic_name;characteristic_level,characteristic_level
174,p - blocker,characteristic_name;characteristic_level,characteristic_level
175,nmbr - nmbr,characteristic_name;characteristic_level,characteristic_level
176,prior coronary revascularization,characteristic_name;characteristic_level,characteristic_level
177,unstable angina,characteristic_name;characteristic_level,characteristic_level
178,"time from onset of pain to randomization , median ( iqr ) , h",characteristic_name;characteristic_level,characteristic_name
179,st - segment depression > nmbr . nmbr mv,characteristic_name;characteristic_level,characteristic_level
180,age > nmbr y,characteristic_name;characteristic_level,characteristic_level
181,ace inhibitor or angiotensin ii receptor blocker,characteristic_name;characteristic_level,characteristic_level
182,aspirin,characteristic_name;characteristic_level,characteristic_level
183,"weight , median ( iqr ) , kg",characteristic_name;characteristic_level,characteristic_level
184,white race,characteristic_name;characteristic_level,characteristic_name
185,non - st - elevation mi,characteristic_name;characteristic_level,characteristic_level
186,colon,characteristic_level;measures,characteristic_level
187,mean ( sd ),characteristic_level;measures,characteristic_level
188,perianal or anus,characteristic_level;measures,characteristic_level
189,"mean weight ( sd ) , kg",characteristic_level;measures,characteristic_level
190,"previous loss of response to infliximab , n ( % ) *",characteristic_level;measures,characteristic_level
191,mean cdai score ( sd ),characteristic_level;measures,characteristic_level
192,"crp concentration > nmbr mg / l , n ( % ) \",characteristic_level;measures,characteristic_level
193,"men , n ( % )",characteristic_level;measures,characteristic_level
194,"current smoker , n ( % )",characteristic_level;measures,characteristic_level
195,present,characteristic_level;measures,characteristic_name
196,other,characteristic_level;measures,characteristic_level
197,gastroduodenal,characteristic_level;measures,characteristic_level
198,any immunosuppressive agent,characteristic_level;measures,characteristic_level
199,jejunum,characteristic_level;measures,characteristic_level
200,acute reaction,characteristic_level;measures,characteristic_level
201,median ( range ),characteristic_level;measures,characteristic_level
202,ileum,characteristic_level;measures,characteristic_level
203,"previous intolerance of infliximab , n ( % ) *",characteristic_level;measures,characteristic_name
204,delayed reaction,characteristic_level;measures,characteristic_name
205,"abdominal or perianal fistula at baseline , n ( % )",characteristic_level;measures,characteristic_name
206,"previous loss of response to and intolerance of infliximab , n ( % ) *",characteristic_level;measures,characteristic_level
207,"mean baseline ibdq score ( sd ) § crp concentration , mg / l",characteristic_level;measures,characteristic_level
208,steroids § §,characteristic_level;measures,characteristic_name
209,indeterminate ! !,characteristic_level;measures,characteristic_level
210,acute and delayed reaction,characteristic_level;measures,characteristic_level
211,rectum,characteristic_level;measures,characteristic_level
212,absent,characteristic_level;measures,characteristic_level
213,nmbr - aminosalicylates | | | |,characteristic_level;measures,characteristic_level
214,"mean age ( sd ) , y",characteristic_level;measures,characteristic_level
215,certolizumab group ( n = nmbr ),arms;measures,arms
217,placebo group ( n = nmbr ) f,arms;measures,arms
218,colon,characteristic_name;measures,characteristic_level
219,previous infliximab therapy — no . of patients ( % ) * *,characteristic_name;measures,characteristic_name
220,geometric mean,characteristic_name;measures,characteristic_level
221,median,characteristic_name;measures,characteristic_level
222,cdai score §,characteristic_name;measures,characteristic_level
223,neither glucocorticoids nor immunosuppressive agents,characteristic_name;measures,characteristic_level
224,terminal ileum,characteristic_name;measures,characteristic_level
225,disease site — no . of patients ( % ) |,characteristic_name;measures,characteristic_name
226,immunosuppressive agents only,characteristic_name;measures,characteristic_level
227,concurrent treatment of crohn ' s disease at study entry — no . of patients ( % ) ff,characteristic_name;measures,characteristic_name
228,glucocorticoids plus immunosuppressive agents,characteristic_name;measures,characteristic_level
229,glucocorticoids only,characteristic_name;measures,characteristic_level
230,range,characteristic_name;measures,characteristic_level
231,duration of disease — yr,characteristic_name;measures,characteristic_level
232,ileocolon,characteristic_name;measures,characteristic_level
233,age — yr,characteristic_name;measures,characteristic_level
234,crp — mg / liter^,characteristic_name;measures,characteristic_level
235,current smoker — no . of patients ( % ),characteristic_name;measures,characteristic_level
236,mean ± sd,characteristic_name;measures,characteristic_level
237,previous bowel resection performed — no . of patients ( % ),characteristic_name;measures,characteristic_level
238,body - mass index : ! :,characteristic_name;measures,characteristic_name
239,mean,characteristic_name;measures,characteristic_level
240,previous acute hypersensitivity reaction to infliximab — no . of patients ( % ),characteristic_name;measures,characteristic_level
241,male sex — no . of patients ( % ),characteristic_name;measures,characteristic_level
243,p - valuea,arms;measures,characteristic_level
245,rrr ( nmbr % cl ),arms;measures,arms
246,interactionnmbr,arms;measures,characteristic_level
247,nmbr . nmbr ( nmbr . nmbr - nmbr . nmbr ),arms;measures,characteristic_level
248,nmbr . nmbr,arms;measures,characteristic_level
249,id genotype,measures;other,characteristic_level
250,p,measures;other,characteristic_level
251,adjustednmbr risk reduction losartan vs placebo ( nmbr % cl ),arms;measures;p-interaction,arms
252,"losartan , n / n ( % )",arms;measures;p-interaction,arms
253,f * >,arms;measures;p-interaction,characteristic_level
254,"placebo , n / n ( % )",arms;measures;p-interaction,arms
255,total study population ( n = nmbr ),arms;other,characteristic_level
256,amlodipine / valsartan nmbr / nmbr mg ( n = nmbr ),arms;other,arms
257,amlodipine / valsartan nmbr / nmbr mg ( n = nmbri ),arms;other,arms
259,aspirin ( n = nmbr nmbr ),arms;measures,characteristic_level
261,aspirin group ( n = nmbr nmbr ) ( nmbr nmbr person years ),arms;measures,characteristic_level
262,placebo group ( n = nmbr nmbr ) ( nmbr nmbr person years ),arms;measures,arms
263,hazard ratio * ( nmbr % ci ),arms;measures,measures
266,all patients ( « = nmbr nmbr ),arms;measures,characteristic_level
267,atenolol ( « = nmbr nmbr ),arms;measures,arms
268,verapamil - sr ( « = nmbr nmbr ),arms;measures,arms
271,atenolol strategy,arms;measures,arms
272,verapamil - sr strategy,arms;measures,arms
273,all ( n = nmbr ),arms;measures,characteristic_level
275,denosumab ( n = nmbr ),arms;measures,arms
276,lumbar spine bmd t - score,characteristic_name;characteristic_level,characteristic_name
277,age ( yr ),characteristic_name;characteristic_level,characteristic_level
278,serum ctx ( ng / ml ),characteristic_name;characteristic_level,characteristic_level
279,> nmbr yr since menopause,characteristic_name;characteristic_level,characteristic_name
280,serum pnmbrnp ( ^g / liter ),characteristic_name;characteristic_level,characteristic_name
281,years since menopause,characteristic_name;characteristic_level,characteristic_name
282,bodymass index ( kg / mnmbr ),characteristic_name;characteristic_level,characteristic_name
283,< nmbr yr since menopause,characteristic_name;characteristic_level,characteristic_name
284,serum trap - nmbrb ( u / liter ),characteristic_name;characteristic_level,characteristic_name
285,p - value,measures;p-interaction,measures
286,standard ( n = nmbr ),measures;p-interaction,arms
287,aggressive ( n = nmbr ),measures;p-interaction,characteristic_level
288,age ( yrs ) < nmbr,characteristic_name;characteristic_level,characteristic_level
289,> nmbr,characteristic_name;characteristic_level,characteristic_level
290,gender male,characteristic_name;characteristic_level,characteristic_level
291,female,characteristic_name;characteristic_level,characteristic_level
292,egfr < nmbr,characteristic_name;characteristic_level,characteristic_level
293,crp ( mg / dl ) < nmbr . nmbr,characteristic_name;characteristic_level,characteristic_level
294,nmbr . nmbr - nmbr . nmbr,characteristic_name;characteristic_level,characteristic_level
295,bmi ( kg / mnmbr ) < nmbr,characteristic_name;characteristic_level,characteristic_level
296,non - hdl ( mg / dl ) < nmbr,characteristic_name;characteristic_level,characteristic_level
297,ale < nmbr,characteristic_name;characteristic_level,characteristic_level
298,sbp ( mmhg ) < nmbr,characteristic_name;characteristic_level,characteristic_level
299,current smoker yes,characteristic_name;characteristic_level,characteristic_level
301,no,characteristic_name;characteristic_level,characteristic_level
302,> nmbr . nmbr,characteristic_name;characteristic_level,characteristic_level
303,ldl - c ( mg / dl ) < nmbr,characteristic_name;characteristic_level,characteristic_level
304,epa group n = nmbr,arms;measures,arms
306,no epa group n = nmbr,arms;measures,arms
307,epa group no . of events ( % ),measures;p-interaction,arms
308,p value,measures;p-interaction,measures
309,"hr , nmbr % cl",measures;p-interaction,measures
310,no epa group no . of events ( % ),measures;p-interaction,arms
311,metoprolol group ( n = nmbr ),arms;measures,arms
313,valsartan ( n = nmbr ),arms;p-interaction,arms
314,p *,arms;p-interaction,characteristic_level
315,valsartan / hctz ( n = nmbr ),arms;p-interaction,arms
317,"valsartan / hctz , n / n ( % )",arms;p-interaction,arms
318,"valsartan , n / n ( % )",arms;p-interaction,arms
319,valsartan,arms;p-interaction,arms
320,p,arms;p-interaction,characteristic_level
321,valsartan / hctz,arms;p-interaction,arms
322,proactive intervention ( n = nmbra ),arms;measures,characteristic_name
323,usual care ( n = nmbra ),arms;measures,arms
324,p valuenmbr,arms;measures,arms
325,usual care ( n = nmbrla ),arms;measures,arms
326,standard control ( n = nmbr ) no . of patients ( percent ),arms;measures,arms
327,intensive control ( n = nmbr ) no . of patients ( percent ),arms;measures,arms
328,relative risk reduction ( nmbr % cl ) percent,arms;measures,measures
329,value,arms;measures,measures
330,arm,arms;measures,characteristic_level
331,risk,arms;measures,characteristic_name
332,n,arms;measures,characteristic_level
333,atenolol n = nmbr no . ( % ),arms;measures,arms
334,hr ( nmbr % cl ),arms;measures,measures
335,verapamil sr n = nmbr no . ( % ),arms;measures,arms
336,aspirin - erdp clopidogrel no . of patients / total no .,arms;measures,characteristic_level
337,hr ( nmbr % cl ) *,arms;measures,measures
338,rosuvastatin events / patients ( % ),arms;measures,arms
339,placebo events / patients ( % ),arms;measures,measures
342,n - nmbr pufa events / patients ( % ),arms;measures,measures
344,p inleraclion,arms;measures;p-interaction,characteristic_level
345,aspirin group,arms;measures;p-interaction,arms
346,rr ( nmbr % ci ) *,arms;measures;p-interaction,measures
347,subgroup by treatment interaction p - value,arms;p-interaction,measures
348,placebo,arms;p-interaction,arms
349,p value for interaction,arms;p-interaction,measures
350,irbesartan,arms;p-interaction,arms
352,all countries,characteristic_name;characteristic_level,characteristic_level
353,hbanmbrc ( % ) all countries,characteristic_name;characteristic_level,characteristic_level
354,india,characteristic_name;characteristic_level,characteristic_level
355,korea,characteristic_name;characteristic_level,characteristic_level
356,china,characteristic_name;characteristic_level,characteristic_level
357,aliskiren ( n = nmbr ),arms;measures,arms
359,hydochlorothiazide ( n = nmbr ),arms;measures,characteristic_level
364,hr,arms;measures,measures
365,ranozaline,arms;measures,characteristic_level
370,fp nmbr mg,arms;measures,arms
371,total,arms;measures,characteristic_level
373,sfc nmbr mg / nmbr mg,arms;measures,arms
374,sal nmbr mg,arms;measures,arms
375,epa ( mol % ),measures;outcomes,arms
376,hdl - cholesterol ( mg / dl ),measures;outcomes,characteristic_name
377,fpg ( mg / dl ),measures;outcomes,characteristic_level
378,systolic ( mmhg ),measures;outcomes,characteristic_level
379,total cholesterol ( mg / dl ),measures;outcomes,characteristic_name
380,"hba , c ( % )",measures;outcomes,characteristic_level
381,triglyceride ( median : mg / dl ) a [nmbr - nmbr percentile],measures;outcomes,characteristic_level
382,ldl - cholesterol ( mg / dl ),measures;outcomes,characteristic_name
383,diastolic fmmhff ' ),measures;outcomes,characteristic_level
386,non - epa number of <,arms;measures,characteristic_level
387,epa hr events ( % ),arms;measures,measures
388,p value for trend,characteristic_name;p-interaction,measures
389,mmse score,characteristic_name;p-interaction,characteristic_level
391,interaction p value,measures;p-interaction,measures
392,number of events / patients,measures;p-interaction,measures
393,mmse < nmbr,characteristic_name;characteristic_level,characteristic_level
394,mmse nmbr - nmbr,characteristic_name;characteristic_level,characteristic_level
395,all participants,characteristic_name;characteristic_level,characteristic_name
396,mmse > nmbr,characteristic_name;characteristic_level,characteristic_level
397,control,arms;measures,arms
398,tiotropium,arms;measures,arms
400,ratio ( nmbr % ci ) *,arms;measures,measures
401,"rosuvastatin , events / patients ( % )",arms;measures,arms
404,"placebo , events / patients ( % )",arms;measures,measures
405,nmbr % cl,arms;measures,measures
406,lvef > nmbr %,characteristic_name;characteristic_level,characteristic_level
407,lvef < nmbr %,characteristic_name;characteristic_level,characteristic_level
408,non - ischaemic aetiology,characteristic_name;characteristic_level,characteristic_level
409,egfr < nmbr ( ml / min / nmbr . nmbr mnmbr ),characteristic_name;characteristic_level,characteristic_level
410,history of paroxysmal af,characteristic_name;characteristic_level,characteristic_name
411,age > nmbr yearsnmbr,characteristic_name;characteristic_level,characteristic_level
412,nyha lll - iv,characteristic_name;characteristic_level,characteristic_level
413,egfr > nmbr ( ml / min / nmbr . nmbr mnmbr ),characteristic_name;characteristic_level,characteristic_level
414,nyha ii,characteristic_name;characteristic_level,characteristic_level
415,age < nmbr yearsnmbr,characteristic_name;characteristic_level,characteristic_level
416,ischemic aetiology,characteristic_name;characteristic_level,characteristic_level
417,total cholesterolnmbr < nmbr mg / dl,characteristic_name;characteristic_level,characteristic_level
418,no diabetes,characteristic_name;characteristic_level,characteristic_name
420,total cholesterolnmbr > nmbr mg / dl,characteristic_name;characteristic_level,characteristic_level
421,no history of paroxysmal af,characteristic_name;characteristic_level,characteristic_name
422,p value for heterogeneity,arms;p-interaction,measures
423,placebo ( n = nmbr ),arms;p-interaction,arms
424,fluvastatin ( n = nmbr ),arms;p-interaction,arms
425,value,arms;measures;outcomes,measures
426,arm,arms;measures;outcomes,characteristic_level
427,outcome,arms;measures;outcomes,characteristic_name
428,reteplase / abciximab - facilitated pci ( n = nmbr ),arms;measures,arms
430,primary pci ( n = nmbr ),arms;measures,characteristic_level
431,abciximab - facilitated pci ( n = nmbr ),arms;measures,arms
432,primary pci,arms;measures,characteristic_level
434,ret / abx - facil . pci,arms;measures,characteristic_name
436,hazard ratio,arms;measures,measures
439,abx - facil . pci,arms;measures,characteristic_name
442,odds ratio ( nmbr % cl ),arms;measures,measures
444,alteplase,arms;measures,arms
446,hr ( nmbr % ci ),arms;measures;p-interaction,measures
447,p - value,arms;measures;p-interaction,measures
448,interaction p - valuenmbr,arms;measures;p-interaction,arms
449,"p , subgroup *",arms;measures;p-interaction,characteristic_level
450,"rosuvastatin , n ( rate )",arms;measures;p-interaction,arms
451,hr ( nmbr % cl ),arms;measures;p-interaction,measures
452,"p , interaction !",arms;measures;p-interaction,characteristic_name
453,"placebo , n ( rate )",arms;measures;p-interaction,arms
454,combination therapy ( n = nmbr ),arms;measures,characteristic_level
455,all patients ( n = nmbr ),arms;measures,characteristic_level
456,infliximab ( n = nmbr ),arms;measures,arms
457,azathioprine ( n = nmbr ),arms;measures,characteristic_level
458,p valued,arms;measures,characteristic_level
460,difference,arms;measures,measures
462,mean yearly decline,arms;measures,characteristic_level
464,events,arms;measures,measures
466,p value for interaction,arms;measures;p-interaction,measures
467,relative risk ( nmbr % confidence interval ),arms;measures;p-interaction,characteristic_name
468,macce ( % ),arms;measures;p-interaction,characteristic_level
469,"absolute risk difference ( ci ) , % *",arms;measures,measures
470,"placebo , n / n ( % )",arms;measures,arms
471,"extended - duration enoxaparin , n / n ( % )",arms;measures,arms
472,placebo ( n[nmbr ),arms;measures,arms
474,sfc ( n[nmbr ),arms;measures,arms
475,fp ( n[nmbr ),arms;measures,arms
476,salmeterol ( n[nmbr ),arms;measures,arms
478,placebo group,arms;measures,arms
479,ivabradine group,arms;measures,arms
480,"all with coenzyme qnmbr ( n = nmbr , nmbr )",measures;characteristic_level,characteristic_level
481,tertile nmbr ( n = nmbr ),measures;characteristic_level,characteristic_level
482,p value for trend across tertiles,measures;characteristic_level,measures
483,subgroup p valuef,arms;measures,characteristic_level
485,interaction p value 中,arms;measures,measures
486,placebo n ( rate ) *,arms;measures,arms
487,type of end point,arms;measures,characteristic_name
489,rosuvastatin n ( rate ),arms;measures,arms
490,noncardiovascular,characteristic_level;outcomes,characteristic_level
491,tertile nmbr,characteristic_level;outcomes,characteristic_level
492,cardiovascular,characteristic_level;outcomes,characteristic_name
493,worsening heart failure,characteristic_level;outcomes,characteristic_name
494,all - cause,characteristic_level;outcomes,characteristic_name
495,rolofylline,arms;measures,arms
497,ldl - c,measures;outcomes,characteristic_name
498,apob,measures;outcomes,characteristic_name
499,"final mean , mg / dl",measures;outcomes,characteristic_name
500,tg,measures;outcomes,characteristic_level
501,"final median , mg / l",measures;outcomes,characteristic_level
502,"median change , %",measures;outcomes,characteristic_level
503,hdl - c,measures;outcomes,characteristic_name
504,"baseline mean , mg / dl",measures;outcomes,characteristic_level
505,/ ’ - valuenmbr ’,measures;outcomes,arms
506,"mean change , % ( se )",measures;outcomes,measures
507,non - hdl - c,measures;outcomes,characteristic_level
508,hscrp,measures;outcomes,characteristic_level
509,"/ ’ - value """,measures;outcomes,measures
510,"baseline median , mg / l",measures;outcomes,characteristic_level
511,"weight $ nmbr . nmbr kg , n",measures;characteristic_level,characteristic_level
512,"no extensive colitis , n",measures;characteristic_level,characteristic_level
513,"mayo < nmbr , n",measures;characteristic_level,characteristic_level
514,difference from placebo ( nmbr % ci ),measures;characteristic_level,measures
515,"remission , n ( % )",measures;characteristic_level,characteristic_level
516,"corticosteroid ( without imm ) , n",measures;characteristic_level,characteristic_level
517,"immy ( without corticosteroid ) , n",measures;characteristic_level,characteristic_level
518,difference from placebo * ( nmbr % ci ),measures;characteristic_level,measures
519,"extensive colitis , n",measures;characteristic_level,characteristic_level
520,"aminosalicylates , n",measures;characteristic_level,characteristic_level
521,"weight < nmbr . nmbr kg , n",measures;characteristic_level,characteristic_level
522,"weight $ nmbr . nmbr kg , < nmbr . nmbr kg , n",measures;characteristic_level,characteristic_level
523,"no aminosalicylates , n",measures;characteristic_level,characteristic_level
524,"crp < nmbr mg / l , n",measures;characteristic_level,characteristic_level
525,"no corticosteroid + no imm , n",measures;characteristic_level,characteristic_level
526,"crp $ nmbr mg / l , n",measures;characteristic_level,characteristic_level
527,"imm + corticosteroid , n",measures;characteristic_level,characteristic_level
528,"mayo $ nmbr , n",measures;characteristic_level,characteristic_level
530,bosentan,arms;measures,arms
533,p value *,arms;measures,measures
535,"rolofylline ( n = nmbr , nmbr )",arms;measures,arms
536,sfc ( n = nmbr ),arms;measures,arms
537,total population ( n = nmbr ),arms;measures,characteristic_level
539,total ho population ( n = nmbr ),arms;measures,characteristic_level
540,fp ( n = nmbr ),arms;measures,arms
541,sal ( n = nmbr ),arms;measures,characteristic_level
542,"czp nmbr mg , % ( n / n )",arms;measures,arms
544,"placebo , % > ( n / n )",arms;measures,arms
545,odds ratio,arms;measures,measures
547,"czp nmbr mg , % ( n / n )",arms;measures;p-interaction,arms
548,p value,arms;measures;p-interaction,measures
549,odds ratio,arms;measures;p-interaction,measures
550,nmbr % cl,arms;measures;p-interaction,measures
551,"placebo , % ( n / n )",arms;measures;p-interaction,arms
553,rr^ ( nmbr % ci ),arms;measures,measures
554,asa,arms;measures,characteristic_level
555,r | r ' ' ' ( nmbr % ci ),arms;measures,measures
557,current smoker,characteristic_level;measures,characteristic_level
558,diabetes mellitus,characteristic_level;measures,characteristic_level
559,hyperlipidemia^,characteristic_level;measures,characteristic_level
560,hypertension *,characteristic_level;measures,characteristic_level
561,history of chd,characteristic_level;measures,characteristic_name
562,male,characteristic_level;measures,characteristic_level
563,history of carotid artery disease,characteristic_level;measures,characteristic_name
564,history of peripheral artery disease,characteristic_level;measures,characteristic_level
565,range,characteristic_level;measures,characteristic_level
566,history of pci,characteristic_level;measures,characteristic_name
567,p,p-interaction;other,characteristic_level
568,group b ( n = nmbr ),p-interaction;other,arms
569,group a ( n = nmbr ),p-interaction;other,arms
570,group c ( n = nmbr ),p-interaction;other,arms
571,cox hr ( nmbr % ci ),arms;measures,measures
572,cmh rr ( nmbr % ci ),arms;measures,measures
573,"total comparators , patients with events / total patients",arms;measures,measures
574,"linagliptin , patients with events / total patients",arms;measures,measures
575,"hazard ratio ( nmbr % cl ) nmbr . nmbr ( nmbr . nmbr , nmbr . nmbr )",arms;measures;p-interaction,measures
576,vorapaxar placebo nmbr - yr %,arms;measures;p-interaction,arms
577,p - value for interaction,arms;measures;p-interaction,measures
578,p - value for interaction,arms;p-interaction,measures
579,nonmetabolic syndrome ( n = nmbr ),measures;characteristic_level,characteristic_level
580,p value,measures;characteristic_level,measures
581,metabolic syndrome ( n = nmbr ),measures;characteristic_level,characteristic_level
582,"patients without ra , as , or psa ( n = nmbr , nmbr )",arms;measures,characteristic_level
584,"patients with ra , as , or psa ( n = nmbr )",arms;measures,characteristic_level
585,simvastatin nmbr mg ( n = nmbr ),arms;measures,arms
586,"atorvastatin nmbr mg ( n = nmbr , nmbr )",arms;measures,arms
587,p +,arms;measures,characteristic_level
588,"simvastatin nmbr mg ( n = nmbr , nmbr )",arms;measures,arms
589,atorvastatin nmbr mg ( n = nmbr ),arms;measures,arms
592,standard care n ( % ) / nmbrpy,arms;measures,arms
593,insulin glargine n ( % ) / nmbrpy,arms;measures,arms
595,"age , y , mean ( sd )",characteristic_level;measures,characteristic_level
596,"egfr , ml / min / nmbr . nmbr mnmbr , mean ( sd )",characteristic_level;measures,characteristic_level
597,"> nmbr y , no . ( % )",characteristic_level;measures,characteristic_level
598,prediabeticb,characteristic_level;measures,characteristic_level
600,normoglycemicnmbr,characteristic_level;measures,characteristic_level
601,"hbanmbrc , % , mean ( sd )",characteristic_level;measures,characteristic_level
602,median,characteristic_level;measures,characteristic_level
603,diabeticnmbr,characteristic_level;measures,characteristic_level
608,"tc , mg / dl , mean + sd",characteristic_name;characteristic_level,characteristic_level
609,"male , n ( % )",characteristic_name;characteristic_level,characteristic_level
610,nmbr - year framingham chd risk ( % ) nmbr mean / sd ),characteristic_name;characteristic_level,characteristic_level
611,asian,characteristic_name;characteristic_level,characteristic_level
612,"bmi , kg / mnmbr , mean + sd",characteristic_name;characteristic_level,characteristic_level
613,"race , n ( % )",characteristic_name;characteristic_level,characteristic_name
614,"hdl - c , mg / dl , mean + sd",characteristic_name;characteristic_level,characteristic_level
615,"sbp , mm hg , mean + sdc",characteristic_name;characteristic_level,characteristic_level
616,white,characteristic_name;characteristic_level,characteristic_level
617,"ldl - c , mg / dl , mean + sd",characteristic_name;characteristic_level,characteristic_level
619,"dbp , mm hg , mean ± sdc",characteristic_name;characteristic_level,characteristic_level
620,"age , years , mean ± sd",characteristic_name;characteristic_level,characteristic_level
621,vorapaxar placebo nmbr - yr . km %,arms;measures,arms
622,hr ( nmbr % ci ) p value for interaction *,arms;measures,measures
624,"fevnmbr reversibility , % b",characteristic_name;characteristic_level,characteristic_level
625,"ex - smoker / smoker , %",characteristic_name;characteristic_level,characteristic_level
626,baseline dyspnea index score,characteristic_name;characteristic_level,characteristic_name
627,"severity of copd , n ( % ) ( gold nmbr ) : moderate",characteristic_name;characteristic_level,characteristic_name
628,severe / very severea,characteristic_name;characteristic_level,characteristic_level
630,"age , years",characteristic_name;characteristic_level,characteristic_name
631,"duration of copd , years",characteristic_name;characteristic_level,characteristic_name
632,black,characteristic_name;characteristic_level,characteristic_level
633,"fevnmbr ( pre - albuterol ) , l",characteristic_name;characteristic_level,characteristic_name
634,"fevnmbr ( post - albuterol ) , l",characteristic_name;characteristic_level,characteristic_name
635,"sex , male / female , %",characteristic_name;characteristic_level,characteristic_level
636,"smoking history , pack - years",characteristic_name;characteristic_level,characteristic_name
637,"fevnmbr % pred . ( post - albuterol ) , %",characteristic_name;characteristic_level,characteristic_level
638,baseline sgrq score,characteristic_name;characteristic_level,characteristic_level
639,"ics use , yes / no %",characteristic_name;characteristic_level,characteristic_level
640,fevnmbr / fvc ( post - albuterol ),characteristic_name;characteristic_level,characteristic_level
641,"race , % caucasian",characteristic_name;characteristic_level,characteristic_name
642,sgrq total score,measures;outcomes,characteristic_level
643,locf ),measures;outcomes,characteristic_level
644,sgrq total score ( week,measures;outcomes,characteristic_level
645,bdi total score ( baseline ),measures;outcomes,characteristic_level
646,change from baseline,measures;outcomes,measures
647,tdi total score ( week nmbr,measures;outcomes,characteristic_level
648,( baseline ),measures;outcomes,characteristic_name
649,nmbr locf ),measures;outcomes,characteristic_level
650,"male / female , %",characteristic_name;characteristic_level,characteristic_level
651,"fevnmbr , la",characteristic_name;characteristic_level,characteristic_level
652,taiwan,characteristic_name;characteristic_level,characteristic_level
653,japanese,characteristic_name;characteristic_level,characteristic_level
654,reversibility to,characteristic_name;characteristic_level,characteristic_name
655,"fevnmbr / fvc , % a",characteristic_name;characteristic_level,characteristic_level
656,"ics use , %",characteristic_name;characteristic_level,characteristic_name
659,ex - smoker / current,characteristic_name;characteristic_level,characteristic_level
660,korean,characteristic_name;characteristic_level,characteristic_level
661,"fevnmbr , % predicteda",characteristic_name;characteristic_level,characteristic_level
662,"duration of copd ,",characteristic_name;characteristic_level,characteristic_name
663,"smoking history ,",characteristic_name;characteristic_level,characteristic_name
664,indian,characteristic_name;characteristic_level,characteristic_level
665,"copd severity , n ( % )",characteristic_name;characteristic_level,characteristic_name
666,m o nito ring treatment,arms;p-interaction;other,characteristic_name
667,r elative risk ( nmbr % ci ),arms;p-interaction;other,measures
668,p interaction,arms;p-interaction;other,characteristic_name
669,conventional treatment,arms;p-interaction;other,characteristic_name
674,n - nmbr - pufa ( n = nmbr ),arms;other,arms
675,placebo ( n = nmbr ),arms;other,arms
676,* p value,arms;other,measures
677,( nmbr % cl ) interaction,arms;p-interaction,measures
678,n - nmbr pufa,arms;p-interaction,arms
680,peri - op statins : no ( n = nmbr ),characteristic_name;characteristic_level,characteristic_level
681,serum potassium : < nmbr . nmbrmmol / l ( n = nmbr ),characteristic_name;characteristic_level,characteristic_level
682,study drug loading days ( actual ) : nmbr ( n = nmbr ),characteristic_name;characteristic_level,characteristic_level
683,phospholipid omega - nmbr levels : < nmbr % ( n = nmbr ),characteristic_name;characteristic_level,characteristic_level
684,overall ( n = nmbr ),characteristic_name;characteristic_level,characteristic_level
685,sex : male ( n = nmbr ),characteristic_name;characteristic_level,characteristic_level
686,peri - op beta - blockers : no ( n = nmbr ),characteristic_name;characteristic_level,characteristic_level
687,habitual fish intake : < nmbr servings / wk ( n = nmbr ),characteristic_name;characteristic_level,characteristic_level
688,on - pump time : < l : nmbrhrs : min ( n = nmbr ),characteristic_name;characteristic_level,characteristic_level
689,ejection fraction : < nmbr % ( n = nmbr ),characteristic_name;characteristic_level,characteristic_level
690,cross - damp time : < l : llhrs : min ( n = nmbr ),characteristic_name;characteristic_level,characteristic_name
691,age : < nmbr years ( n = nmbr ),characteristic_name;characteristic_level,characteristic_level
692,cardiac valve surgery : no ( n = nmbr ),characteristic_name;characteristic_level,characteristic_level
693,left atrial diameter : < nmbr mm ( n = nmbr ),characteristic_name;characteristic_level,characteristic_level
694,peri - op ace - inhibitors / arbs : no ( n = nmbr ),characteristic_name;characteristic_level,characteristic_level
695,hypertension : no ( n = nmbr ),characteristic_name;characteristic_level,characteristic_level
696,peri - op amiodarone : no ( n = nmbr ),characteristic_name;characteristic_level,characteristic_level
697,nyha class nmbr - nmbr : no { n = llll ),characteristic_name;characteristic_level,characteristic_level
698,country : argentina ( n = nmbr ),characteristic_name;characteristic_level,characteristic_level
699,% change median baseline crp > nmbrmg / l,measures;characteristic_name,characteristic_level
700,baseline crp < nmbrmg / l,measures;characteristic_name,characteristic_name
701,baseline,measures;other,characteristic_name
702,change from baseline,measures;other,measures
703,week nmbr,measures;other,characteristic_level
704,feno placebo ( lsm ),measures;other,arms
705,lsm difference,measures;other,measures
706,placebo ( lsm ),measures;other,arms
707,p value,measures;other,measures
708,( nmbr % ci ),measures;other,measures
709,omalizumab ( lsm ),measures;other,characteristic_level
710,fibrinolysis ( n = nmbr ),arms;other,characteristic_level
711,p valuey,arms;other,characteristic_level
712,primary pci ( n = nmbr ),arms;other,characteristic_level
713,p value for interaction,arms;measures;p-interaction;other,measures
714,relative risk ( nmbr % ci ) ofprimary end point,arms;measures;p-interaction;other,measures
715,fibrinolysis primary pci ( n = nmbr ) ( n = nmbr ) no . of patients / total no . ( % ),arms;measures;p-interaction;other,characteristic_level
716,p value,arms;measures;p-interaction;other,measures
717,watchman ( n = nmbr ),arms;other,characteristic_level
718,control ( n = nmbr ),arms;other,arms
719,p value,arms;other,measures
720,interactior p - value,measures;p-interaction,measures
721,n - nmbr fatty acids - placebo lsm ( nmbr % cl ),measures;p-interaction,arms
722,diabetes,measures;characteristic_name,characteristic_name
723,p,measures;characteristic_name,characteristic_level
724,all,measures;characteristic_name,characteristic_level
725,no diabetes,measures;characteristic_name,characteristic_name
726,visits nmbrenmbr,measures;other,characteristic_level
727,univariate p - value,measures;other,measures
728,multivariate p - value,measures;other,measures
729,change from baseline in hbanmbrc ( % ),measures;characteristic_name;other,characteristic_level
730,p - value,measures;characteristic_name;other,measures
731,"patients with egfr > nmbr ml / min / nmbr . nmbrmnmbr , n",measures;characteristic_name;other,characteristic_level
732,nmbr % ci,measures;characteristic_name;other,measures
733,"patients with egfr nmbr > nmbr to < nmbr ml / min / nmbr . nmbrmnmbr , n",measures;characteristic_name;other,characteristic_level
734,difference vs . placebo,measures;characteristic_name;other,arms
736,veflonzumao,arms;measures,characteristic_level
737,estimated difference %,arms;measures,measures
741,control ( n - nmbr ),arms;measures,arms
742,statin ( n - nmbr ),arms;measures,characteristic_level
743,events / control group,arms;measures;p-interaction,arms
745,orc ( nmbr % cl ),arms;measures;p-interaction,measures
746,oradj ( nmbr % cl ),arms;measures;p-interaction,measures
747,events / statin group,arms;measures;p-interaction,arms
748,p for interaction,arms;measures;p-interaction,characteristic_name
749,hazard ratio ( nmbr % cl ),measures;p-interaction;outcomes,measures
750,interaction p value,measures;p-interaction;outcomes,measures
751,p value,measures;p-interaction;outcomes,measures
752,event rate ( % ) of primary endpoints,measures;p-interaction;outcomes,characteristic_name
753,ipst ( n = nmbr ),p-interaction;outcomes,characteristic_level
754,"no ipst ( n = nmbr , nmbr )",p-interaction;outcomes,characteristic_level
755,p value,p-interaction;outcomes,measures
756,or [nmbr % ci],arms;measures;p-interaction,measures
757,p [int],arms;measures;p-interaction,characteristic_level
758,no ipst,arms;measures;p-interaction,characteristic_level
759,ipst,arms;measures;p-interaction,characteristic_level
760,"ff / vi nmbr / nmbr gg ( n = nmbr , nmbr )",arms;measures,arms
761,"total ( n = nmbr , nmbr )",arms;measures,characteristic_level
762,"ff nmbr gg ( n = nmbr , nmbr )",arms;measures,arms
763,indacaterol nmbr ug ( n = nmbr ),arms;measures,arms
765,total ( n = nmbr ),arms;measures,characteristic_level
766,ics use at baseline : yes,characteristic_name;characteristic_level,characteristic_level
767,moderate or less airflow limitation,characteristic_name;characteristic_level,characteristic_level
768,sex : male,characteristic_name;characteristic_level,characteristic_level
769,sex : female,characteristic_name;characteristic_level,characteristic_name
770,age : > nmbr years,characteristic_name;characteristic_level,characteristic_level
771,reversibility : < nmbr %,characteristic_name;characteristic_level,characteristic_level
772,bmi : < nmbr . nmbr kg / mnmbr,characteristic_name;characteristic_level,characteristic_level
773,reversibility : > nmbr %,characteristic_name;characteristic_level,characteristic_level
774,smoking : ex - smoker,characteristic_name;characteristic_level,characteristic_level
775,age : < nmbr years,characteristic_name;characteristic_level,characteristic_level
776,overall,characteristic_name;characteristic_level,characteristic_level
777,bmi : > nmbr . nmbr kg / mnmbr,characteristic_name;characteristic_level,characteristic_level
778,ics use at baseline : no,characteristic_name;characteristic_level,characteristic_name
779,severe or worse airflow limitation,characteristic_name;characteristic_level,characteristic_level
780,reversibility : > nmbr - < nmbr %,characteristic_name;characteristic_level,characteristic_level
781,smoking : current smoker,characteristic_name;characteristic_level,characteristic_level
782,nmbrmg vs placebo,measures;p-interaction,arms
783,p - value ( lnteraction ),measures;p-interaction,measures
784,age < nmbryrs,characteristic_name;characteristic_level,characteristic_name
786,bl h / y : bilateral,characteristic_name;characteristic_level,characteristic_level
787,bl updrs : high,characteristic_name;characteristic_level,characteristic_level
788,bl h / y : unilateral,characteristic_name;characteristic_level,characteristic_level
789,age nmbr + yrs,characteristic_name;characteristic_level,characteristic_level
790,male,characteristic_name;characteristic_level,characteristic_level
791,bl updrs : low,characteristic_name;characteristic_level,characteristic_level
792,placebo,characteristic_name;characteristic_level,arms
793,men,characteristic_name;characteristic_level,characteristic_level
794,education nmbr - nmbr years,characteristic_name;characteristic_level,characteristic_level
795,depression,characteristic_name;characteristic_level,characteristic_name
796,hbak > median,characteristic_name;characteristic_level,characteristic_level
797,hbalc > median,characteristic_name;characteristic_level,characteristic_level
798,age < nmbr years,characteristic_name;characteristic_level,characteristic_level
799,education > nmbr years,characteristic_name;characteristic_level,characteristic_level
800,hba < median,characteristic_name;characteristic_level,characteristic_level
802,omega - nmbr fatty acid,characteristic_name;characteristic_level,arms
803,hbak < median,characteristic_name;characteristic_level,characteristic_level
807,women,characteristic_name;characteristic_level,characteristic_level
808,no depression,characteristic_name;characteristic_level,characteristic_name
809,education < nmbr years,characteristic_name;characteristic_level,characteristic_level
810,number insulin glargine,measures;p-interaction,characteristic_level
811,p nmbr interaction,measures;p-interaction,characteristic_level
812,number standard care,measures;p-interaction,arms
813,insulin glargine vs standard care least - squares mean ( nmbr % cl ),measures;p-interaction,arms
814,number omega - nmbr number placeb fatty acid,measures;p-interaction,characteristic_name
815,p . interaction,measures;p-interaction,characteristic_name
816,omega - nmbr fatty acid vs placebo least - squares mean ( nmbr % cl ),measures;p-interaction,arms
821,insulin glargine,characteristic_name;characteristic_level,arms
823,hbalc < median,characteristic_name;characteristic_level,characteristic_level
830,standard care,characteristic_name;characteristic_level,arms
833,p : interaction,measures;p-interaction,characteristic_name
834,unadjusted hr,measures;p-interaction,measures
835,number ( % ),measures;p-interaction,characteristic_name
837,without beta blocker,characteristic_name;characteristic_level,characteristic_level
838,family history of diabetes ( - ),characteristic_name;characteristic_level,characteristic_name
839,fbs < nmbr mg / dl,characteristic_name;characteristic_level,characteristic_level
840,with acei / arb,characteristic_name;characteristic_level,characteristic_level
841,age > = nmbr years old,characteristic_name;characteristic_level,characteristic_name
842,age < nmbr years old,characteristic_name;characteristic_level,characteristic_name
843,bmi < nmbrkg / mnmbr,characteristic_name;characteristic_level,characteristic_level
844,family history of diabetes ( + ),characteristic_name;characteristic_level,characteristic_name
845,all patients,characteristic_name;characteristic_level,characteristic_level
846,without acei / arb,characteristic_name;characteristic_level,characteristic_level
847,bmi > = nmbrkg / mnmbr,characteristic_name;characteristic_level,characteristic_level
849,fbs > = nmbr mg / dl,characteristic_name;characteristic_level,characteristic_level
850,with beta blocker,characteristic_name;characteristic_level,characteristic_level
852,relative risk ( nmbr % cl ),arms;measures;p-interaction,measures
853,continuation,arms;measures;p-interaction,arms
854,interruption,arms;measures;p-interaction,arms
859,primary pci n = nmbr,arms;measures,characteristic_level
860,relative risk ( nmbr % cl ),arms;measures,measures
862,pharmaco - invasive n = nmbr,arms;measures,arms
863,p - value ( int ),measures;p-interaction,measures
864,endpoint rate,measures;p-interaction,characteristic_level
866,interact !,arms;measures;p-interaction,characteristic_level
867,fp / sal nmbr / nmbr pg ( n = nmbr ),arms;measures,arms
868,sal nmbr pg ( n = nmbr ),arms;measures,characteristic_level
870,saxa + dapa + met n = nmbr,arms;measures,arms
871,dapa + met n = nmbr,arms;measures,arms
872,total n = nmbr,arms;measures,characteristic_level
873,saxa + met n = nmbr,arms;measures,arms
874,hr ( nmbr % ci ),arms;other,measures
875,device group,arms;other,arms
876,warfarin group,arms;other,arms
877,continued thienopyridine n ( % ),arms;measures;p-interaction;other,arms
878,placebo n ( % ),arms;measures;p-interaction;other,arms
879,hrnmbr and nmbr % cl,arms;measures;p-interaction;other,measures
881,n,arms;measures;p-interaction;other,characteristic_level
882,"placebo ( n = nmbr , nmbr )",arms;p-interaction,arms
884,"vorapaxar ( n = nmbr , nmbr )",arms;p-interaction,arms
886,hazard ratio,measures;p-interaction,measures
887,p - interaction,measures;p-interaction,characteristic_name
888,total study population,characteristic_name;characteristic_level,characteristic_level
889,women > nmbr years,characteristic_name;characteristic_level,characteristic_level
890,women < nmbr years,characteristic_name;characteristic_level,characteristic_level
891,statin ( n = nmbr ),arms;other,characteristic_level
893,p - value,arms;other,measures
894,"placebo ( n = nmbr , nmbr )",arms;measures;p-interaction,arms
896,"saxagliptin nmbr . nmbr mg ( n = nmbr , nmbr )",arms;measures;p-interaction,arms
897,"saxagliptin nmbr mg ( n = nmbr , nmbr )",arms;measures;p-interaction,arms
898,p,arms;measures;p-interaction,characteristic_level
899,placebo ( n = nmbr ),arms;measures;p-interaction,arms
900,p for interaction *,arms;measures;p-interaction,characteristic_name
901,saxagliptin nmbr . nmbr mg ( n = nmbr ),arms;measures;p-interaction,arms
902,nmbr yr km % ( n ),measures;p-interaction,characteristic_level
903,hr ( nmbr % cl ),measures;p-interaction,measures
904,p - value for interaction,measures;p-interaction,measures
905,no dm ( n = nmbr ),measures;characteristic_level,characteristic_level
907,dm ( n = nmbr ),measures;characteristic_level,characteristic_level
908,p value ( int ),arms;measures;p-interaction,measures
911,"vorapaxar event rate ( n = nmbr ) , %",arms;measures;p-interaction,characteristic_name
912,"placebo event rate ( n = nmbr ) , %",arms;measures;p-interaction,arms
915,rivaroxaban,arms;measures,arms
916,hr,measures;p-interaction,measures
918,nmbr % cl,measures;p-interaction,measures
921,nmbr % ci,measures;p-interaction,measures
922,> = nmbr years,measures;characteristic_level,characteristic_level
923,< nmbr years,measures;characteristic_level,characteristic_level
924,p value § ( < nmbr vs . > = nmbr years ),measures;characteristic_level,characteristic_level
925,saxagliptin,arms;measures,arms
927,"> = nmbr years ( placebo n = nmbr , nmbr ; saxagliptin n = nmbr , nmbr )",characteristic_level;p-interaction,arms
928,"< nmbr years ( placebo n = nmbr , nmbr ; saxagliptin n = nmbr , nmbr )",characteristic_level;p-interaction,arms
929,interaction p value,characteristic_level;p-interaction,measures
930,patients,arms;measures;p-interaction,characteristic_level
931,ticagrelor nmbr mg nmbr year km ( % ),arms;measures;p-interaction,arms
932,interaction p - value,arms;measures;p-interaction,measures
934,placebo nmbr year km ( % ),arms;measures;p-interaction,arms
936,vorapaxar placebo nmbr - yr . km % rate,arms;measures;p-interaction,arms
937,total no .,arms;measures;p-interaction,characteristic_level
939,p vs placebo,arms;measures,arms
941,any statin,characteristic_name;characteristic_level,characteristic_level
943,hispanic / latino,characteristic_name;characteristic_level,characteristic_level
944,lp ( a ) §,characteristic_name;characteristic_level,characteristic_level
945,median ( qnmbr : qnmbr ),characteristic_name;characteristic_level,characteristic_level
946,non - hdl - c,characteristic_name;characteristic_level,characteristic_level
947,high - dose statin use at screening *,characteristic_name;characteristic_level,characteristic_name
948,ldl - c ( measured ) *,characteristic_name;characteristic_level,characteristic_name
949,other llt use,characteristic_name;characteristic_level,characteristic_name
950,ezetimibe use,characteristic_name;characteristic_level,characteristic_name
951,fasting tgs §,characteristic_name;characteristic_level,characteristic_name
952,hdl - c,characteristic_name;characteristic_level,characteristic_name
954,apo b,characteristic_name;characteristic_level,characteristic_name
955,"chd risk equivalents , n ( % )",characteristic_name;characteristic_level,characteristic_name
956,"bmi , kg / mnmbr , mean ( sd )",characteristic_name;characteristic_level,characteristic_level
957,"any cv history / risk factors , n ( % )",characteristic_name;characteristic_level,characteristic_name
958,ldl - c ( calculated ) *,characteristic_name;characteristic_level,characteristic_name
959,"ethnicity , n ( % )",characteristic_name;characteristic_level,characteristic_name
960,black or african american,characteristic_name;characteristic_level,characteristic_level
961,"type nmbr diabetes , n ( % )",characteristic_name;characteristic_level,characteristic_name
962,"chd history , n ( % )",characteristic_name;characteristic_level,characteristic_name
963,"age , y , mean ( sd )",characteristic_name;characteristic_level,characteristic_level
965,minimum : maximum,characteristic_name;characteristic_level,characteristic_name
967,aiirocumab,arms;measures;p-interaction,arms
968,n,arms;measures;p-interaction,characteristic_level
969,consistency of effect,arms;measures;p-interaction,characteristic_level
970,placebo estimated mean,arms;measures;p-interaction,characteristic_name
972,never,measures;characteristic_level,characteristic_level
973,> nmbr years,measures;characteristic_level,characteristic_level
975,overall,measures;characteristic_level,characteristic_level
977,eastern europe,measures;characteristic_level,characteristic_level
978,asia pacific and other,measures;characteristic_level,characteristic_level
979,> median,measures;characteristic_level,characteristic_level
980,^median,measures;characteristic_level,characteristic_level
981,< nmbr mmhg,measures;characteristic_level,characteristic_level
982,egfr £ nmbr ml / min / nmbr . nmbrmnmbr,measures;characteristic_level,characteristic_level
984,other,measures;characteristic_level,characteristic_level
986,nmbr mmhg,measures;characteristic_level,characteristic_level
987,> = nmbr - < nmbr mmhg,measures;characteristic_level,characteristic_level
988,^median > median,measures;characteristic_level,characteristic_level
989,no,measures;characteristic_level,characteristic_level
990,> nmbr - < nmbr mmhg,measures;characteristic_level,characteristic_level
991,female,measures;characteristic_level,characteristic_level
992,current,measures;characteristic_level,characteristic_level
994,< nmbr kg / mnmbr,measures;characteristic_level,characteristic_level
995,body mass index subgroups,measures;characteristic_level,characteristic_name
996,> nmbr - < nmbr years,measures;characteristic_level,characteristic_level
997,yes ',measures;characteristic_level,characteristic_level
998,north america,measures;characteristic_level,characteristic_level
999,yes,measures;characteristic_level,characteristic_level
1000,> = nmbr mmhg,measures;characteristic_level,characteristic_level
1001,latin america,measures;characteristic_level,characteristic_level
1002,anmbr kg / mnmbr,measures;characteristic_level,characteristic_level
1003,egfr < nmbr ml / min / nmbr . nmbrmnmbr,measures;characteristic_level,characteristic_level
1004,former,measures;characteristic_level,characteristic_level
1005,male,measures;characteristic_level,characteristic_level
1006,western europe,measures;characteristic_level,characteristic_level
1008,hr nmbr % ci,arms;measures;p-interaction,measures
1009,ranolazine vs . placebo km failure rate,arms;measures;p-interaction,arms
1010,pfor interaction,arms;measures;p-interaction,measures
1011,nnmbr / nnmbr,arms;measures,arms
1012,lsm ( nmbr % cl ),arms;measures,measures
1013,placebo mean ( n ),arms;measures,arms
1014,estimated difference,arms;measures,measures
1015,liraglutide nmbr . nmbr mg mean ( n ),arms;measures,arms
1016,warfarin,arms;measures,characteristic_name
1017,hr nmbr % cl,arms;measures,measures
1018,p for i,arms;measures,characteristic_level
1020,apixaban,arms;measures,arms
1021,apixaban vs . placebo,arms;measures,arms
1023,control,arms;measures;p-interaction,arms
1024,odds ratio ( nmbr % cl ),arms;measures;p-interaction,measures
1025,p - value for interaction nmbr . nmbr,arms;measures;p-interaction,measures
1026,cyclo,arms;measures;p-interaction,characteristic_level
1027,% change from baseline ls means ( se ),measures;p-interaction,measures
1028,interaction p - value,measures;p-interaction,measures
1029,placebo n = nmbr,arms;measures,arms
1030,all n = nmbr,arms;measures,characteristic_level
1031,vorapaxar n = nmbr,arms;measures,arms
1032,all n = nmbr nmbr,arms;measures,characteristic_level
1033,no thienopyridine,characteristic_level;p-interaction,arms
1034,tp vs no tp,characteristic_level;p-interaction,arms
1035,thienopyridine,characteristic_level;p-interaction,arms
1037,p - int,arms;measures;p-interaction,characteristic_level
1038,hr,arms;measures;p-interaction,measures
1039,vora,arms;measures;p-interaction,characteristic_level
1040,plac,arms;measures;p-interaction,characteristic_level
1041,age > = nmbr,characteristic_name;characteristic_level,characteristic_level
1042,"sex , male",characteristic_name;characteristic_level,characteristic_level
1043,"renal function , moderate",characteristic_name;characteristic_level,characteristic_name
1044,"renal function , normal - mild",characteristic_name;characteristic_level,characteristic_level
1045,oretal,characteristic_name;characteristic_level,characteristic_level
1046,mrf subjects,characteristic_name;characteristic_level,characteristic_level
1047,"sex , female",characteristic_name;characteristic_level,characteristic_name
1048,"race , non - white",characteristic_name;characteristic_level,characteristic_level
1049,"region , europe",characteristic_name;characteristic_level,characteristic_name
1050,"race , while",characteristic_name;characteristic_level,characteristic_name
1051,"region , asia / paafic",characteristic_name;characteristic_level,characteristic_name
1052,age < nmbr,characteristic_name;characteristic_level,characteristic_level
1053,"region , europe union",characteristic_name;characteristic_level,characteristic_level
1054,cvd subjects,characteristic_name;characteristic_level,characteristic_level
1055,"region , north america",characteristic_name;characteristic_level,characteristic_level
1056,"renal function , severe",characteristic_name;characteristic_level,characteristic_name
1057,"region , latin america",characteristic_name;characteristic_level,characteristic_level
1058,( nmbr % ci ),measures;p-interaction,measures
1064,patients with event / patients analyzed,measures;p-interaction,characteristic_level
1066,cangrelor,arms;measures,arms
1067,clopidogrel,arms;measures,arms
1068,p interaction,arms;measures;p-interaction,characteristic_name
1069,cangrelor,arms;measures;p-interaction,arms
1070,clopidogrel,arms;measures;p-interaction,arms
1071,or ( nmbr % cl ),arms;measures;p-interaction,measures
1072,brv nmbr mg / day ( n = nmbr ),arms;measures,arms
1073,pbo ( n = nmbr ),arms;measures,arms
1075,< nmbr days ( n = nmbr ),arms;measures;p-interaction,characteristic_level
1076,( n = nmbr ),arms;measures;p-interaction,characteristic_level
1083,p interaction,arms;measures;p-interaction;outcomes,characteristic_name
1084,hr ( nmbr % cl ),arms;measures;p-interaction;outcomes,measures
1085,outcome,arms;measures;p-interaction;outcomes,characteristic_name
1086,placebo ( % ),arms;measures;p-interaction,arms
1088,saxagliptin ( % ),arms;measures;p-interaction,arms
1094,"incidence , %",measures;p-interaction,measures
1096,placebo %,arms;measures;p-interaction,arms
1098,continued thienopyridine %,arms;measures;p-interaction,arms
1100,p value for interactiont,arms;measures;p-interaction,measures
1101,pvalue,arms;measures,characteristic_level
1102,treatment arm,arms;measures,characteristic_name
1103,hazard ratio ( nmbr % confi dence interval ),arms;measures;p-interaction,measures
1104,warfarin,arms;measures;p-interaction,characteristic_name
1107,laa closure,arms;measures;p-interaction,characteristic_level
1108,stent ( n = nmbr ),arms;measures,characteristic_level
1110,subgroup,arms;measures,characteristic_level
1112,medical therapy ( n = nmbr ),arms;measures,characteristic_name
1113,hazard ratio ( nmbr % cl ),arms;measures,measures
1114,medical therapy,arms;measures,characteristic_name
1116,stent,arms;measures,characteristic_name
1118,standard care n ( % ),arms;measures;p-interaction,arms
1119,insulin glargine n ( x ),arms;measures;p-interaction,arms
1122,hazard ratio,arms;measures;p-interaction,measures
1124,selexipag ( n = nmbr ),arms;measures,characteristic_level
1126,liraglutide nmbr . nmbr mg ls means ( n ),arms;p-interaction,arms
1127,etd ( % ) [nmbr % ci],arms;p-interaction,measures
1128,placebo ls means ( n ),arms;p-interaction,arms
1129,change from baseline ( % ),measures;p-interaction,measures
1130,no of events women men *,measures;p-interaction,characteristic_level
1131,"ratio of hrs ( nmbr % ci ) , p for sex interaction",measures;p-interaction,measures
1132,no of events womenmen *,measures;p-interaction,measures
1133,"ratio of hrs ( nmbr % cl ) , p for sex interaction",measures;p-interaction,measures
1135,female subgroup,measures;characteristic_level,characteristic_level
1136,p value ( cangrelor versus clopidogrel in men ),measures;characteristic_level,arms
1137,p value ( cangrelor versus clopidogrel in women ),measures;characteristic_level,arms
1138,women ( n = nmbr ),measures;characteristic_level,characteristic_level
1139,p value ( men versus women ),measures;characteristic_level,characteristic_level
1140,men ( n = nmbr ),measures;characteristic_level,characteristic_level
1141,n / n ( % ),arms;measures;p-interaction,characteristic_level
1142,interaction p value,arms;measures;p-interaction,measures
1143,hazard ratio ( nmbr % cl ),measures;p-interaction,measures
1144,"nmbr - wk kaplan - meier rate , %",measures;p-interaction,characteristic_level
1145,total no .,measures;p-interaction,characteristic_level
1147,"events , no .",measures;p-interaction,measures
1148,pvaluefor any mi versus no mi,measures;characteristic_level,characteristic_level
1149,"no mi ( n - nmbr , nmbr )",measures;characteristic_level,characteristic_level
1150,"index mi ( n - nmbr , nmbr )",measures;characteristic_level,characteristic_level
1151,"any mi ( n - nmbr , nmbr )",measures;characteristic_level,characteristic_level
1152,"prior mi ( n - nmbr , nmbr )",measures;characteristic_level,characteristic_level
1153,"diabetes ( n - nmbr , nmbr )",measures;characteristic_level,characteristic_level
1155,"no diabetes ( n - nmbr , nmbr )",measures;characteristic_level,characteristic_level
1156,"no pad ( n - nmbr , nmbr )",arms;measures,characteristic_level
1158,"pad ( n - nmbr , nmbr )",arms;measures,characteristic_level
1159,rosuvastatin,arms;measures,arms
1161,trend / het . test,arms;measures,characteristic_name
1164,percentage difference ( nmbr % cl ),arms;measures,measures
1165,heterogeneity test,arms;measures,characteristic_name
1171,all patients n = nmbr,arms;measures,characteristic_level
1172,pbo + mtx n = nmbr,arms;measures,arms
1173,czp + mtx n = nmbr,arms;measures,arms
1174,rate ratio ( nmbr % cl ),arms;measures,measures
1175,salmeterol - fluticasone group,arms;measures,arms
1176,indacaterol - glycopyrronium group,arms;measures,arms
1178,liraglutide,arms;measures,arms
1181,us ( n = nmbr ),arms;measures,characteristic_level
1182,non - us ( n = nmbr ),arms;measures,characteristic_level
1184,or ( nmbr % ci ),arms;measures,measures
1187,us ( n = nmbr ),characteristic_level;p-interaction,characteristic_level
1188,non - us ( n = nmbr ),characteristic_level;p-interaction,characteristic_level
1189,"p , treatment - by - region interaction",characteristic_level;p-interaction,characteristic_name
1190,"p , regional difference",characteristic_level;p-interaction,measures
1192,p - value,measures;characteristic_level,measures
1193,asia - pacific,measures;characteristic_level,characteristic_level
1194,central / eastern europe / russia,measures;characteristic_level,characteristic_level
1197,asia - pacific hr ( nmbr % cl ),measures;characteristic_level;p-interaction,characteristic_level
1198,latin america hr ( nmbr % cl ),measures;characteristic_level;p-interaction,characteristic_level
1199,overall hr ( nmbr % cl ),measures;characteristic_level;p-interaction,characteristic_level
1200,north america hr ( nmbr % cl ),measures;characteristic_level;p-interaction,characteristic_level
1201,central / eastern europe and russia hr ( nmbr % cl ),measures;characteristic_level;p-interaction,characteristic_level
1202,pfor interaction,measures;characteristic_level;p-interaction,measures
1203,western europe hr ( nmbr % cl ),measures;characteristic_level;p-interaction,characteristic_level
1204,nmbr - nmbr months fn = nmbr . nmbr ),measures;characteristic_level,characteristic_level
1205,nmbr - nmbr months ( n = nmbr ),measures;characteristic_level,characteristic_level
1207,< nmbr months in - nmbr kill,measures;characteristic_level,characteristic_level
1208,"no prior hf hospitalization ( n = nmbr , nmbr )",measures;characteristic_level,characteristic_level
1209,"> nmbr months ( n = nmbr , nmbr )",measures;characteristic_level,characteristic_level
1210,"event rates , %",measures;p-interaction,characteristic_name
1211,p - value for variance,measures;p-interaction,measures
1212,relative risk ( nmbr % ci ),measures;p-interaction,measures
1215,p value fo interactio,arms;measures;p-interaction,measures
1216,placebo no . / total no .,arms;measures;p-interaction,arms
1217,sitagliptin no . / total no .,arms;measures;p-interaction,arms
1218,prior hypertensiona yes,characteristic_name;characteristic_level,characteristic_level
1220,diuretic thiazide,characteristic_name;characteristic_level,characteristic_level
1221,"> nmbr egfr , ml / min / nmbr . nmbr mnmbr",characteristic_name;characteristic_level,characteristic_level
1222,< nmbr,characteristic_name;characteristic_level,characteristic_level
1223,"systolic blood pressure , mm hg < nmbr",characteristic_name;characteristic_level,characteristic_name
1225,eastern europe,characteristic_name;characteristic_level,characteristic_level
1226,region latin american,characteristic_name;characteristic_level,characteristic_level
1227,asia pacific and other,characteristic_name;characteristic_level,characteristic_level
1228,> median,characteristic_name;characteristic_level,characteristic_level
1229,baseline heart failure severity nyha class i,characteristic_name;characteristic_level,characteristic_name
1230,body mass indexa < median,characteristic_name;characteristic_level,characteristic_name
1231,> nmbr to < nmbr,characteristic_name;characteristic_level,characteristic_level
1233,glycated hemoglobin < median,characteristic_name;characteristic_level,characteristic_name
1235,"> nmbr to < nmbr egfr , ml / min / nmbr . nmbr mnmbr a",characteristic_name;characteristic_level,characteristic_level
1236,racea white,characteristic_name;characteristic_level,characteristic_level
1237,nyha class not reported,characteristic_name;characteristic_level,characteristic_name
1239,prior coronary artery disease yes,characteristic_name;characteristic_level,characteristic_level
1240,prior myocardial infarction yes,characteristic_name;characteristic_level,characteristic_level
1241,age < median,characteristic_name;characteristic_level,characteristic_level
1242,prior congestive heart failure yes,characteristic_name;characteristic_level,characteristic_level
1243,thiazolidinedione yes,characteristic_name;characteristic_level,characteristic_level
1245,ace inhibitor yes,characteristic_name;characteristic_level,characteristic_level
1246,p - blocker yes,characteristic_name;characteristic_level,characteristic_level
1247,"> nmbr egfr , ml / min / nmbr . nmbr mnmbr a",characteristic_name;characteristic_level,characteristic_level
1248,none,characteristic_name;characteristic_level,characteristic_level
1249,sexa male,characteristic_name;characteristic_level,characteristic_level
1250,north america,characteristic_name;characteristic_level,characteristic_level
1252,diabetes durationa < median,characteristic_name;characteristic_level,characteristic_level
1253,nyha class > ii,characteristic_name;characteristic_level,characteristic_level
1254,insulin yes,characteristic_name;characteristic_level,characteristic_level
1255,angiotensin receptor blocker yes,characteristic_name;characteristic_level,characteristic_level
1256,not hispanic or latino,characteristic_name;characteristic_level,characteristic_level
1257,"renal function < nmbr egfr , ml / min / nmbr . nmbr mnmbr",characteristic_name;characteristic_level,characteristic_level
1258,ethnicitya hispanic or latino,characteristic_name;characteristic_level,characteristic_level
1259,western europe,characteristic_name;characteristic_level,characteristic_level
1260,placebo events / n ( % ),arms;measures,arms
1261,pioglitazone events / n ( % ),arms;measures,arms
1262,p - value *,arms;measures,measures
1264,log rank p - value,arms;measures;p-interaction,measures
1265,placebo n ( % ),arms;measures;p-interaction,arms
1267,p value for adjusted hr,arms;measures;p-interaction,measures
1268,adjusted p - value for interaction,arms;measures;p-interaction,measures
1269,adjusted hr ( nmbr % ci ),arms;measures;p-interaction,measures
1270,unadjusted p - value for interaction,arms;measures;p-interaction,measures
1271,ticagrelor nmbr mg vs . placebo hr ( nmbr % ci ),arms;measures;p-interaction,arms
1272,placebo nmbr yr km %,arms;measures;p-interaction,arms
1273,p - interaction,arms;measures;p-interaction,characteristic_name
1274,number of patients,arms;measures;p-interaction,characteristic_level
1275,ticagrelor nmbr mg nmbr yr km %,arms;measures;p-interaction,characteristic_level
1276,p - interactio n,arms;measures;p-interaction,characteristic_level
1277,monitoring treatment,arms;measures;p-interaction,characteristic_name
1279,hazard ratio ( nmbr % ci ),arms;measures;p-interaction,measures
1280,conventional treatment,arms;measures;p-interaction,characteristic_name
1285,"acs ( n - nmbr , nmbr )",measures;characteristic_level,characteristic_level
1286,"stable angina ( n - nmbr , nmbr )",measures;characteristic_level,characteristic_level
1288,inter p - value,arms;measures,measures
1290,or ( nmbr % cl ),arms;measures,measures
1291,statin users ( n = nmbr ),arms;measures,characteristic_level
1292,statin non - users ( n = nmbr ),arms;measures,characteristic_level
1301,tocilizumab ( n = nmbr ),arms;measures,characteristic_level
1302,peripheral revascularization ( n = nmbr ),arms;measures,characteristic_level
1303,"no peripheral revascularization ( n = nmbr , nmbr )",arms;measures,characteristic_level
1305,"patients receiving lcz , no . ( % )",arms;measures,characteristic_name
1306,incidencea,arms;measures,characteristic_level
1307,"patients receiving enl , no . ( % )",arms;measures,characteristic_name
1309,adjusted hr ( enl vs lcz ) ( nmbr % cl ),arms;measures,measures
1310,hr ( enl vs lcz ) ( nmbr % cl ),arms;measures,measures
1313,nmbr mg sirukumab every nmbr weeks ( n = nmbr ),arms;measures,arms
1315,pioglitazone pts / n ( % ),arms;measures,arms
1316,placebo pts / n ( % ),arms;measures,arms
1318,copd ( n = nmbr ),arms;measures,characteristic_name
1319,copd - placebo ( n = nmbr ),arms;measures,arms
1321,copd - rosuvastatin ( n = nmbr ),arms;measures,arms
1322,unadjusted,arms;measures,characteristic_level
1323,adjusted,arms;measures,arms
1325,empagliflozin,arms;measures;p-interaction,arms
1327,placebo,arms;measures;p-interaction,arms
1329,placebo n / n ( % ),arms;measures;p-interaction,arms
1331,ularitide n / n ( % ),arms;measures;p-interaction,characteristic_level
1332,no . pts,arms;measures;p-interaction,characteristic_level
1333,placebo / open - label abatacept,arms;measures,arms
1334,abatacept,arms;measures,arms
1335,abatacept / open - label abatacept,arms;measures,arms
1337,estimated difference ( nmbr % ci ),arms;measures,measures
1338,canagliflozin,arms;measures;p-interaction,characteristic_level
1344,treatment difference,arms;measures,measures
1345,linagliptin,arms;measures,arms
1347,number of participants,measures;p-interaction,characteristic_name
1350,or ( nmbr % ci ),arms;measures;p-interaction,measures
1351,"cangrelor , %",arms;measures;p-interaction,arms
1352,"clopidogrel , %",arms;measures;p-interaction,arms
1354,rivaroxaban + aspirin,arms;measures;p-interaction,arms
1355,"hazard ratio for cardiovascular death , stroke , or myocardial infarction ( nmbr % ci )",arms;measures;p-interaction,characteristic_name
1356,aspirin alone,arms;measures;p-interaction,arms
1357,phi ( n = nmbr ),arms;measures,characteristic_level
1358,ppci ( n = nmbr ),arms;measures,characteristic_name
1361,rr,arms;measures,characteristic_level
1362,phi ( n - nmbr ),arms;measures,characteristic_level
1363,ppci in - nmbr,arms;measures,characteristic_name
1364,( nmbr % cl ),arms;measures,measures
1365,anacetrapib ( n = nmbr ),arms;measures;p-interaction,arms
1366,p - value interaction,arms;measures;p-interaction,measures
1367,hdl - c,arms;measures;p-interaction,characteristic_name
1369,non - hdl - c,arms;measures;p-interaction,characteristic_level
1370,rate ratio,arms;measures;p-interaction,measures
1371,p values,arms;measures,characteristic_name
1372,difference ( tiotropium - placebo ) ml ( nmbr % ci ),arms;measures,arms
1376,monthnmbr,measures;other,characteristic_level
1377,month nmbr,measures;other,arms
1379,mepolizumab group,arms;measures,arms
1381,any statin,characteristic_level;measures,characteristic_level
1382,"median ( qnmbr : qnmbr ) lp ( a ) , mg / dl",characteristic_level;measures,characteristic_level
1383,> nmbr years,characteristic_level;measures,characteristic_level
1384,asian / oriental,characteristic_level;measures,characteristic_level
1385,"mean ( s . d . ) apob , mg / dl",characteristic_level;measures,characteristic_level
1386,"mean ( s . d . ) systolic blood pressure , mm hg",characteristic_level;measures,characteristic_name
1387,"mean ( s . d . ) diastolic blood pressure , mm hg",characteristic_level;measures,characteristic_name
1388,"ascvd , n ( % )",characteristic_level;measures,characteristic_level
1389,hispanic or latino,characteristic_level;measures,characteristic_level
1390,mg / dl,characteristic_level;measures,characteristic_level
1391,mmol / l,characteristic_level;measures,characteristic_name
1393,moderate ’,characteristic_level;measures,characteristic_level
1394,statin monotherapy,characteristic_level;measures,characteristic_level
1395,any other llts ( other than statin ),characteristic_level;measures,characteristic_level
1396,chda,characteristic_level;measures,characteristic_level
1397,"mean ( s . d . ) free pcsknmbr , ng / ml",characteristic_level;measures,characteristic_level
1398,any other antihyperglycaemic drugs,characteristic_level;measures,characteristic_name
1399,insulin,characteristic_level;measures,characteristic_level
1400,"micro - / macro - albuminuria , ckd and / or retinopathy",characteristic_level;measures,characteristic_name
1401,white,characteristic_level;measures,characteristic_level
1403,< nmbr years,characteristic_level;measures,characteristic_level
1404,"mean ( s . d . ) hbalc , mmol / mol",characteristic_level;measures,characteristic_level
1405,not reported / unknown,characteristic_level;measures,characteristic_level
1406,"statin intolerancenmbr , n ( % )",characteristic_level;measures,characteristic_level
1407,"mean ( s . d . ) apoc - ll nmbr , mg / dl",characteristic_level;measures,characteristic_level
1408,"median ( qnmbr : qnmbr ) duration of insulin use , years",characteristic_level;measures,characteristic_level
1409,"no ascvd + additional cv risk factors , n ( % )",characteristic_level;measures,characteristic_name
1410,"mean ( s . d . ) ldl particle size , nm",characteristic_level;measures,characteristic_name
1411,"mean ( s . d . ) egfr , ml / min / nmbr . nmbr mnmbr",characteristic_level;measures,characteristic_level
1412,"mean ( s . d . ) ldl particle number , nmol / l",characteristic_level;measures,characteristic_name
1413,"mean ( s . d . ) hbalc , %",characteristic_level;measures,characteristic_level
1414,black,characteristic_level;measures,characteristic_level
1415,biguanides ( metformin ),characteristic_level;measures,characteristic_level
1416,iu,characteristic_level;measures,characteristic_name
1417,"ckdc , n ( % )",characteristic_level;measures,characteristic_level
1418,"male , n ( % )",characteristic_level;measures,characteristic_level
1419,"mean ( s . d . ) total pcsknmbr , ng / ml",characteristic_level;measures,characteristic_level
1420,cholesterol absorption inhibitor ( ezetimibe ),characteristic_level;measures,characteristic_level
1421,"mean ( s . d . ) bmi , kg / mnmbr",characteristic_level;measures,characteristic_level
1422,"mean ( s . d . ) age , years",characteristic_level;measures,characteristic_level
1423,low ’,characteristic_level;measures,characteristic_level
1424,> nmbr additional cv risk factorsnmbr,characteristic_level;measures,characteristic_name
1425,> nmbr to < nmbr years,characteristic_level;measures,characteristic_level
1426,not hispanic or latino,characteristic_level;measures,characteristic_level
1427,high *,characteristic_level;measures,characteristic_level
1428,lu / kg,characteristic_level;measures,characteristic_level
1429,"median ( qnmbr : qnmbr ) duration of diabetes , years",characteristic_level;measures,characteristic_level
1430,"hbalc < nmbr % ( < nmbr mmol / mol ) , n ( % )",characteristic_level;measures,characteristic_level
1431,hdl cholesterol ( week nmbr ) a,measures;outcomes,characteristic_name
1432,apob ( week nmbr ),measures;outcomes,characteristic_level
1433,total cholesterol ( week nmbr ),measures;outcomes,characteristic_name
1434,calculated ldl cholesterol ( week nmbr ),measures;outcomes,characteristic_name
1435,lp ( a ) ( week nmbr ),measures;outcomes,characteristic_level
1436,triglycerides ( week nmbr ) a,measures;outcomes,characteristic_level
1437,ldl particle size ( week nmbr ),measures;outcomes,characteristic_name
1438,non - hdl cholesterol ( week nmbr ),measures;outcomes,characteristic_name
1439,mg / dl,measures;outcomes,characteristic_level
1440,mmol / l,measures;outcomes,characteristic_name
1441,ls mean ( s . e . ) primary endpoint : % change from baseline to week nmbr,measures;outcomes,measures
1442,ldl particle numbers ( week nmbr ),measures;outcomes,characteristic_level
1445,ls mean ( se ),measures;p-interaction,measures
1446,n,measures;p-interaction,characteristic_level
1447,ls mean difference ( se ) vs placebo,measures;p-interaction,measures
1448,ertugliflozin nmbr mg ( n = nmbr ),arms;measures,arms
1451,aliskiren dm = nmbr non - dm = nmbr,arms;measures;p-interaction,arms
1452,enalapril dm = nmbr non - dm = nmbr,arms;measures;p-interaction,arms
1453,p - value for interaction *,arms;measures;p-interaction,measures
1454,enalapril + aliskiren dm = nmbr non - dm = nmbr,arms;measures;p-interaction,arms
1455,hazard ratio or differencenmbr ( nmbr % cl ) p - value,arms;measures;p-interaction,measures
1456,hazard ratio or differencenmbr * ( nmbr % cl ) p - value,arms;measures;p-interaction,measures
1457,first hhf,measures;outcomes,characteristic_level
1458,kccq ( nmbr months ),measures;outcomes,characteristic_level
1459,change in nt - probnp at nmbr months ( log - transformed ),measures;outcomes,characteristic_level
1460,cv death,measures;outcomes,outcomes
1461,change in sbp ( nmbr months ),measures;outcomes,characteristic_level
1462,months ( log - transformed ),measures;outcomes,characteristic_level
1463,cv death or first hhf,measures;outcomes,outcomes
1464,death ( all - cause ),measures;outcomes,outcomes
1465,no stroke ( n = nmbr ),outcomes;other,characteristic_level
1466,any stroke ( n = nmbr ),outcomes;other,characteristic_level
1467,p value,outcomes;other,measures
1468,p - int,arms;p-interaction;other,characteristic_level
1469,hr ( nmbr % ci ),arms;p-interaction;other,measures
1470,total patients,arms;p-interaction;other,characteristic_level
1471,simva ( % ),arms;p-interaction;other,characteristic_level
1472,ez / simva < % >,arms;p-interaction;other,characteristic_level
1473,arr ( nmbr % cl ),arms;measures,measures
1474,ez / simva n = nmbr n ( % ),arms;measures,characteristic_level
1475,simva n = nmbr n ( % ),arms;measures,characteristic_level
1477,prior stroke,characteristic_name;p-interaction,characteristic_level
1478,p interaction,characteristic_name;p-interaction,characteristic_name
1479,no prior stroke,characteristic_name;p-interaction,characteristic_level
1480,risk difference,arms;measures,measures
1481,pioglitazone,arms;measures,arms
1484,"complex anatomy ( n - nmbr , nmbr )",arms;other,characteristic_level
1485,"noncomplex anatomy ( n - nmbr , nmbr )",arms;other,characteristic_level
1486,int . p *,arms;measures;p-interaction,characteristic_level
1488,pioglitazone,arms;measures;p-interaction,arms
1490,hr ( nmbr % ci ),arms;p-interaction,measures
1491,low - dose rivaroxaban + aspirin ( n / n ),arms;p-interaction,arms
1492,aspirin alone ( n / n ),arms;p-interaction,arms
1493,pinteraction,arms;p-interaction,characteristic_level
1495,low - dose rivaroxaban + aspirin group,arms;measures;p-interaction,arms
1496,aspirin alone group no of events / total n ( % ),arms;measures;p-interaction,arms
1497,pinteraction,arms;measures;p-interaction,characteristic_level
1498,mean lixi dose ± sd ( lg / day ),outcomes;other,characteristic_name
1499,ls mean difference ± seb,outcomes;other,measures
1501,mean iglar dose ± sd ( u / day ),outcomes;other,characteristic_name
1502,nmbr % confidence interval,outcomes;other,characteristic_name
1503,hbanmbrc ( n ),outcomes;other,characteristic_name
1504,dose ( n ),outcomes;other,characteristic_name
1505,ls mean change ± sea,outcomes;other,measures
1506,etd ( nmbr % ci ),arms;measures,measures
1507,"placebo ,",arms;measures,arms
1508,"liraglutide nmbr . nmbr mg ,",arms;measures,arms
1509,"baseline bmi > nmbr kg / mnmbr , n = nmbr , nmbr change from baseline to nmbr weeks",characteristic_name;p-interaction,characteristic_level
1510,"baseline bmi nmbr to < nmbr kg / mnmbr , n = nmbr , nmbr change from baseline to nmbr weeks",characteristic_name;p-interaction,characteristic_level
1511,interaction p value,characteristic_name;p-interaction,measures
1513,liraglutide nmbr . nmbr mg,arms;measures,arms
1516,"baseline bmi > nmbr kg / mnmbr , n = nmbr change from baseline to nmbr weeks",characteristic_name;p-interaction,characteristic_level
1518,"baseline bmi nmbr to < nmbr kg / mnmbr , n = nmbr change from baseline to nmbr weeks",characteristic_name;p-interaction,characteristic_level
1519,hr ( nmbr % ci ),arms;measures,measures
1520,eze / simva - nmbryr km rale ( % ),arms;measures,arms
1521,pbo / simva - nmbryr km rale ( % ),arms;measures,arms
1522,pin /,arms;p-interaction;other,characteristic_level
1523,placebo / simvastatin,arms;p-interaction;other,arms
1524,p value *,arms;p-interaction;other,measures
1525,ezetimibe / simvastatin,arms;p-interaction;other,arms
1526,pin /,arms;measures;p-interaction,characteristic_level
1527,placebo / simvastatin,arms;measures;p-interaction,arms
1528,p value *,arms;measures;p-interaction,measures
1529,ezetimibe / simvastatin,arms;measures;p-interaction,arms
1530,diabetes absent nmbr ( nmbr . nmbr ),arms;measures,characteristic_level
1532,diabetes present nmbr ( nmbr . nmbr ),arms;measures,characteristic_level
1537,"mvd ( n - nmbr , nmbr )",arms;other,characteristic_level
1539,"no mvd ( n - nmbr , nmbr )",arms;other,characteristic_level
1540,n / n ( % ),measures;p-interaction,characteristic_level
1544,p - value for trend *,arms;measures,measures
1545,"ef > nmbr % hfpef ( n = nmbr , nmbr % )",arms;measures,characteristic_level
1546,"ef < nmbr % hfref ( n = nmbr , nmbr % )",arms;measures,characteristic_level
1547,"ef nmbr - nmbr % hfmref ( n = nmbr , nmbr % )",arms;measures,characteristic_level
1548,ef < nmbr %,characteristic_name;p-interaction,characteristic_level
1549,ef nmbr - nmbr %,characteristic_name;p-interaction,characteristic_level
1550,p - interaction,characteristic_name;p-interaction,characteristic_name
1551,ef > nmbr %,characteristic_name;p-interaction,characteristic_level
1559,placebo + nmbr mg / d of simvastatin ( n = nmbr ),arms;measures,arms
1560,simvastatin ( nmbr / nmbr mg / d ) ( n = nmbr ),arms;measures,arms
1562,males,characteristic_name;characteristic_level,characteristic_level
1563,timi risk score nmbr - nmbr,characteristic_name;characteristic_level,characteristic_name
1564,non - diabetics,characteristic_name;characteristic_level,characteristic_level
1565,prior aspirin,characteristic_name;characteristic_level,characteristic_level
1566,overall effect,characteristic_name;characteristic_level,characteristic_level
1567,elevated troponin,characteristic_name;characteristic_level,characteristic_name
1568,females,characteristic_name;characteristic_level,characteristic_name
1569,< nmbr years,characteristic_name;characteristic_level,characteristic_level
1570,diabetics,characteristic_name;characteristic_level,characteristic_level
1571,no st depression or elevation,characteristic_name;characteristic_level,characteristic_level
1572,> = nmbr yea ' s,characteristic_name;characteristic_level,characteristic_level
1573,st depression or elevation,characteristic_name;characteristic_level,characteristic_level
1574,no prior aspirin,characteristic_name;characteristic_level,characteristic_level
1575,normal troponin,characteristic_name;characteristic_level,characteristic_level
1576,p for interaction,measures;p-interaction,characteristic_name
1577,relative risk ( nmbr % confidence interval ),measures;p-interaction,characteristic_name
1578,no . of events,measures;p-interaction,measures
1581,multivitamin use,characteristic_name;characteristic_level,characteristic_name
1582,premenopausal,characteristic_name;characteristic_level,characteristic_level
1583,mean ( sd ),characteristic_name;characteristic_level,characteristic_level
1584,current,characteristic_name;characteristic_level,characteristic_level
1585,"postmenopausal ,",characteristic_name;characteristic_level,characteristic_level
1586,yes,characteristic_name;characteristic_level,characteristic_level
1588,at least nmbr / mo,characteristic_name;characteristic_level,characteristic_level
1590,"postmenopausal , current hormone",characteristic_name;characteristic_level,characteristic_level
1592,never / rarely,characteristic_name;characteristic_level,characteristic_level
1593,past or never,characteristic_name;characteristic_level,characteristic_level
1594,uncertain,characteristic_name;characteristic_level,characteristic_level
1595,nmbr placebo,arms;measures,arms
1596,nmbr vitamin e,arms;measures,characteristic_level
1599,< nmbr . nmbr,characteristic_name;characteristic_level,characteristic_level
1601,"postmenopausal , current hormone therapy use",characteristic_name;characteristic_level,characteristic_level
1605,"postmenopausal , never or past hormone therapy use",characteristic_name;characteristic_level,characteristic_level
1615,% change from baseline,measures;time/period,measures
1616,baseline median [mg / l],measures;time/period,characteristic_level
1617,cse] +,measures;time/period,characteristic_level
1618,( se] +,measures;time/period,measures
1619,( se]t,measures;time/period,measures
1620,( nmbr % ci] nmbr,measures;time/period,measures
1621,( nmbr % ell ' ll,measures;time/period,characteristic_level
1622,treatment difference,measures;time/period,measures
1623,( mmol / l],measures;time/period,characteristic_name
1624,"baseline mean , mg / dl",measures;time/period,characteristic_level
1625,"baseline median , mg / dl",measures;time/period,characteristic_level
1626,( nmbr % ci]h,measures;time/period,measures
1627,( se ) t *,measures;time/period,measures
1628,cg / ld,measures;time/period,characteristic_name
1629,baseline mean ( mg / dl],measures;time/period,characteristic_level
1630,( se]tf,measures;time/period,characteristic_level
1631,baseline mean,measures;time/period,characteristic_name
1632,( se]t *,measures;time/period,measures
1633,aged ^nmbr years,measures;characteristic_level,characteristic_level
1634,aged < nmbr years,measures;characteristic_level,characteristic_level
1635,p value ( aged > nmbr vs . < nmbr years ),measures;characteristic_level,characteristic_level
1636,pbo n ( % ),arms;measures;p-interaction,arms
1637,atv n ( % ),arms;measures;p-interaction,characteristic_level
1638,rrr,arms;measures;p-interaction,characteristic_level
1640,age - interaction,measures;characteristic_level,characteristic_name
1641,aqe < nmbr,measures;characteristic_level,characteristic_level
1642,total population,measures;characteristic_level,characteristic_level
1643,age < nmbr,measures;characteristic_level,characteristic_level
1644,aqe ^nmbr,measures;characteristic_level,characteristic_level
1645,aqe inmbr,measures;characteristic_level,arms
1646,age ^nmbr,measures;characteristic_level,characteristic_level
1655,pulmonary disease,characteristic_name;characteristic_level,characteristic_name
1656,patients without chronic,characteristic_name;characteristic_level,characteristic_level
1657,patients without diabetesb,characteristic_name;characteristic_level,characteristic_level
1658,subgroups,characteristic_name;characteristic_level,characteristic_name
1659,patients with diabetesb,characteristic_name;characteristic_level,characteristic_level
1661,patients with chronic,characteristic_name;characteristic_level,characteristic_level
1662,hazard ratio for event ( nmbr % ci ),measures;p-interaction,measures
1663,no . of patients,measures;p-interaction,characteristic_level
1665,p - valuec,arms;measures,characteristic_level
1667,differencenmbr,arms;measures,characteristic_level
1673,hazard ratio ( nmbr % ci ),measures;p-interaction,measures
1674,heterogeneity p value,measures;p-interaction,measures
1676,women,characteristic_level;outcomes,characteristic_level
1677,chd + cerebrovascular disease men nmbr / nmbr ( nmbr . nmbr ),characteristic_level;outcomes,characteristic_level
1678,chd men,characteristic_level;outcomes,characteristic_level
1679,men,characteristic_level;outcomes,characteristic_level
1680,hazard ratio ( nmbr % confidence interval ),arms;measures,measures
1681,primary pci no .,arms;measures,characteristic_level
1682,combination - facilitated pci ( % ),arms;measures,characteristic_level
1683,serum triglycerides — mmol / liter,characteristic_name;outcomes,characteristic_name
1684,"glycated hemoglobin , nonstandardized level — %",characteristic_name;outcomes,characteristic_name
1685,"glycated hemoglobin , standardized level — %",characteristic_name;outcomes,characteristic_name
1686,previous vascular disease,characteristic_name;outcomes,characteristic_name
1687,other drugs,characteristic_name;outcomes,characteristic_name
1688,serum cholesterol — mmol / liter,characteristic_name;outcomes,characteristic_name
1689,glucose - lowering drug,characteristic_name;outcomes,characteristic_name
1690,blood pressure — mm hg,characteristic_name;outcomes,characteristic_name
1691,fasting blood glucose — mmol / liter,characteristic_name;outcomes,characteristic_name
1692,region — no . ( % ),characteristic_name;outcomes,characteristic_name
1693,tg > nmbr . hdl < nmbr ( mg / dl ) ( / ? = nmbr ),arms;measures,characteristic_level
1695,"tg < nmbr , hdl > nmbr ( n = nmbr )",arms;measures,characteristic_level
1696,"overall , male : female",characteristic_level;measures,characteristic_level
1697,adas - cog score *,characteristic_level;measures,characteristic_name
1699,mmse score *,characteristic_level;measures,characteristic_level
1700,adcs - adl score *,characteristic_level;measures,characteristic_level
1701,yes,characteristic_level;measures,characteristic_level
1702,"nmbr nmbr years , n ( % )",characteristic_level;measures,characteristic_level
1703,"> nmbr years , n ( % )",characteristic_level;measures,characteristic_level
1706,vadas score *,characteristic_level;measures,characteristic_level
1707,gds score *,characteristic_level;measures,characteristic_level
1708,unknown,characteristic_level;measures,characteristic_level
1709,caucasian,characteristic_level;measures,characteristic_level
1710,mhis score,characteristic_level;measures,characteristic_level
1711,npi - nmbr score *,characteristic_level;measures,characteristic_level
1712,oriental,characteristic_level;measures,characteristic_level
1713,no,characteristic_level;measures,characteristic_level
1715,rates per nmbr patient - years,arms;measures,characteristic_name
1716,subjects randomized,characteristic_level;measures,characteristic_level
1717,completed trial,characteristic_level;measures,characteristic_level
1718,female,characteristic_level;measures,characteristic_level
1720,asian,characteristic_level;measures,characteristic_level
1721,black or african - american,characteristic_level;measures,characteristic_level
1722,adverse eventy,characteristic_level;measures,characteristic_level
1723,discontinued,characteristic_level;measures,characteristic_level
1725,ineffective therapy,characteristic_level;measures,characteristic_name
1727,otherz,characteristic_level;measures,characteristic_level
1730,american indian / alaska native,characteristic_level;measures,characteristic_level
1731,other *,characteristic_level;measures,characteristic_level
1732,non - compliance,characteristic_level;measures,characteristic_level
1736,p value for interaction,arms;measures,measures
1737,total no . of patients,arms;measures,characteristic_level
1738,aspirin only,arms;measures,characteristic_level
1739,clopidogrel plus aspirin % / yr,arms;measures,characteristic_level
1741,total no . of patients,arms;measures;p-interaction,characteristic_level
1742,aspirin only,arms;measures;p-interaction,characteristic_level
1743,clopidogrel plus aspirin % / yr,arms;measures;p-interaction,characteristic_level
1744,"ischemia on cecg ( n = nmbr , nmbr )",measures;characteristic_level,characteristic_level
1745,"no ischemia ( n = nmbr , nmbr )",measures;characteristic_level,characteristic_level
1747,"ranolazine ( n = nmbr , nmbr )",arms;measures,arms
1750,nmbr - i,characteristic_level;outcomes,characteristic_level
1751,coronary angiography during the index hospital stay,characteristic_level;outcomes,characteristic_level
1752,"age , yrs , median ( nmbrth , nmbrth )",characteristic_level;outcomes,characteristic_name
1753,statin,characteristic_level;outcomes,characteristic_level
1754,beta - blocker,characteristic_level;outcomes,characteristic_level
1755,ii,characteristic_level;outcomes,characteristic_level
1756,prior heart failure,characteristic_level;outcomes,characteristic_level
1757,female sex,characteristic_level;outcomes,characteristic_name
1758,prior known stenosis > nmbr %,characteristic_level;outcomes,characteristic_level
1759,thienopyridine,characteristic_level;outcomes,arms
1760,prior mi,characteristic_level;outcomes,characteristic_level
1761,long acting nitratef,characteristic_level;outcomes,characteristic_level
1762,estimated creatinine clearance < nmbr ml / min *,characteristic_level;outcomes,characteristic_name
1763,hyperlipidemia,characteristic_level;outcomes,characteristic_level
1764,age ' ^nmbr yrs,characteristic_level;outcomes,characteristic_level
1765,current smoker,characteristic_level;outcomes,characteristic_level
1766,hypertension,characteristic_level;outcomes,characteristic_level
1767,diabetes mellitus,characteristic_level;outcomes,characteristic_level
1768,calcium - channel blockerf,characteristic_level;outcomes,characteristic_level
1769,ace inhibitor or angiotensin ii receptor blocker,characteristic_level;outcomes,characteristic_level
1770,aspirin,characteristic_level;outcomes,characteristic_level
1771,"weight , kg , median ( nmbrth , nmbrth )",characteristic_level;outcomes,characteristic_name
1772,iii - iv,characteristic_level;outcomes,characteristic_level
1773,white race,characteristic_level;outcomes,characteristic_name
1774,prior coronary revascularization ( pci or cabg ),characteristic_level;outcomes,characteristic_level
1776,diet,arms;measures;p-interaction,arms
1778,diet + pravastatin,arms;measures;p-interaction,arms
1779,middle tg tertile,characteristic_name;characteristic_level,characteristic_level
1780,apob ( mg / dl ),characteristic_name;characteristic_level,characteristic_name
1781,lowest tg tertile,characteristic_name;characteristic_level,characteristic_level
1782,non - hdl cholesterol ( mg / dl ),characteristic_name;characteristic_level,characteristic_name
1783,tgs ( mg / dl ),characteristic_name;characteristic_level,characteristic_name
1784,highest tg tertile,characteristic_name;characteristic_level,characteristic_level
1785,ldl cholesterol ( mg / dl ),characteristic_name;characteristic_level,characteristic_name
1786,non - hdl cholesterol / apob ( ratio ),characteristic_name;characteristic_level,characteristic_name
1787,baseline,measures;time/period,characteristic_name
1788,n,measures;time/period,characteristic_level
1789,treatment,measures;time/period,characteristic_name
1790,n = nmbr,measures;time/period,characteristic_level
1791,"rasagiline , nmbr mg / day",arms;measures,arms
1793,hs - crp > nmbr . nmbr mg / l,measures;characteristic_level,characteristic_level
1794,"p , all vs all",measures;characteristic_level,arms
1795,hs - crp < nmbr . nmbr mg / l,measures;characteristic_level,characteristic_level
1799,p,measures;p-interaction,characteristic_level
1800,"men ( n = nmbr ) , n / n ( % )",measures;p-interaction,characteristic_level
1801,"women ( n = nmbr ) , n / n ( % )",measures;p-interaction,characteristic_level
1803,p interaction women vs men,measures;p-interaction,characteristic_level
1805,ifx + aza ( n = nmbr ),arms;measures,characteristic_level
1807,ifx ( n = nmbr ),arms;measures,characteristic_level
1821,subgroup p valuef,arms;measures;p-interaction,characteristic_level
1822,nmbr % ci,arms;measures;p-interaction,measures
1823,interaction p value 中,arms;measures;p-interaction,measures
1824,placebo n ( rate ) *,arms;measures;p-interaction,arms
1825,type of end point,arms;measures;p-interaction,characteristic_name
1827,rosuvastatin n ( rate ),arms;measures;p-interaction,arms
1833,statin,characteristic_level;measures,characteristic_level
1835,white race — no . / total no . ( % ) $,characteristic_level;measures,characteristic_name
1836,current smoking — no . / total no . ( % ),characteristic_level;measures,characteristic_name
1837,stroke,characteristic_level;measures,characteristic_level
1838,history of gi bleeding or ulcer — no . / total no . ( % ),characteristic_level;measures,characteristic_name
1839,male sex — no . / total no . ( % ),characteristic_level;measures,characteristic_level
1840,current alcohol use — no . / total no . ( % ),characteristic_level;measures,characteristic_name
1842,interquartile range,characteristic_level;measures,characteristic_level
1843,negative for helicobacter pylori — no . / total no . ( % ),characteristic_level;measures,characteristic_level
1844,other vascular disease,characteristic_level;measures,characteristic_name
1845,acs,characteristic_level;measures,characteristic_level
1846,hypertension,characteristic_level;measures,characteristic_level
1847,mi,characteristic_level;measures,characteristic_level
1848,diabetes,characteristic_level;measures,characteristic_name
1849,nsaid use — no . / total no . ( % ),characteristic_level;measures,characteristic_name
1850,pad,characteristic_level;measures,characteristic_level
1851,clopidogrel,characteristic_level;measures,arms
1852,aspirin,characteristic_level;measures,characteristic_level
1853,pci,characteristic_level;measures,characteristic_name
1854,hypercholesterolemia,characteristic_level;measures,characteristic_level
1855,mean acrn,measures;outcomes,characteristic_level
1856,% patients with no progression,measures;outcomes,characteristic_level
1857,change in haq - di ( mean ) t,measures;outcomes,characteristic_level
1858,nmbr % ci,measures;outcomes,measures
1859,major clinical response,measures;outcomes,characteristic_name
1860,joint damage outcomes ( mitt population ),measures;outcomes,characteristic_level
1861,change in dasnmbr - esr ( mean ) i physical function outcomes week nmbr,measures;outcomes,characteristic_name
1862,change in erosion score ( mean ),measures;outcomes,characteristic_level
1863,change in mtss ( mean ),measures;outcomes,measures
1864,or ( unadjusted ),measures;outcomes,characteristic_level
1865,eular good response,measures;outcomes,characteristic_level
1866,% with haq - di decrease > nmbr . nmbr,measures;outcomes,characteristic_level
1867,itt,measures;outcomes,characteristic_level
1868,dasnmbr - esr remission,measures;outcomes,characteristic_name
1869,dasnmbr - esr lda,measures;outcomes,characteristic_name
1870,acrnmbr,measures;outcomes,characteristic_level
1874,placebo patients with events,arms;p-interaction,measures
1875,pvalue for heterogeneity,arms;p-interaction,measures
1876,clopidogrel / total no . of patients % %,arms;p-interaction,characteristic_level
1878,clopidogrel no . of patients % ),arms;p-interaction,characteristic_level
1879,placebo patients with events / total,arms;p-interaction,measures
1880,all patients with opg n - nmbr,measures;characteristic_level,characteristic_level
1881,tertile nmbr ( nmbr . nmbr - nmbr . nmbr pg / ml ) n = nmbr,measures;characteristic_level,characteristic_level
1882,tertile nmbr ( > nmbr . nmbr pg / ml ) n - nmbr,measures;characteristic_level,characteristic_level
1883,p trend,measures;characteristic_level,characteristic_level
1884,tertile nmbr ( < nmbr . nmbr ng / ml ) n - nmbr,measures;characteristic_level,characteristic_level
1885,nmbr % cit,arms;measures;p-interaction,characteristic_level
1886,interaction p value §,arms;measures;p-interaction,measures
1887,rosuvastatin n ( rate ) *,arms;measures;p-interaction,arms
1888,subgroup p value 本,arms;measures;p-interaction,characteristic_level
1890,hazard ratiof,arms;measures;p-interaction,measures
1891,p value for heterogeneity,arms;measures,measures
1894,or nmbr % ci,measures;p-interaction,measures
1896,interaction p,measures;p-interaction,characteristic_name
1897,nadroparin,arms;measures,arms
1899,nadroparin vs control,arms;measures,arms
1900,difference ( nmbr % ci ) *,arms;measures,measures
1901,persistent wrf ( n = nmbr ),arms;measures,characteristic_level
1902,"no persistent wrf ( n = nmbr , nmbr )",arms;measures,characteristic_level
1909,nnt,arms;measures;p-interaction,characteristic_level
1911,interaction - p,arms;measures;p-interaction,characteristic_name
1912,event / patients ( nmbr / pt - y ),arms;measures;p-interaction,measures
1913,ace - i / arb,characteristic_name;characteristic_level,characteristic_level
1914,prior dm,characteristic_name;characteristic_level,characteristic_level
1915,prior cv event,characteristic_name;characteristic_level,characteristic_name
1916,anmbr = nmbr . nmbr % ( median ),characteristic_name;characteristic_level,characteristic_level
1917,ifg / igt,characteristic_name;characteristic_level,characteristic_level
1919,new dm,characteristic_name;characteristic_level,characteristic_level
1920,anmbrc < nmbr . nmbr % ( median ),characteristic_name;characteristic_level,characteristic_level
1921,bmi < = nmbr,characteristic_name;characteristic_level,characteristic_level
1922,age < nmbr yrs,characteristic_name;characteristic_level,characteristic_level
1923,statin use,characteristic_name;characteristic_level,characteristic_name
1924,age > = nmbr yrs,characteristic_name;characteristic_level,characteristic_level
1925,omega nmbr allocation,characteristic_name;characteristic_level,characteristic_level
1927,no statin use,characteristic_name;characteristic_level,characteristic_name
1928,bmi > nmbr,characteristic_name;characteristic_level,characteristic_level
1929,no ace - i / arb,characteristic_name;characteristic_level,characteristic_level
1930,placebo allocation,characteristic_name;characteristic_level,arms
1931,metformin,characteristic_name;characteristic_level,characteristic_level
1932,no prior cv event,characteristic_name;characteristic_level,characteristic_name
1934,no metformin,characteristic_name;characteristic_level,characteristic_level
1936,standard care n ( % ) / nmbrpy,arms;measures;p-interaction,arms
1937,insulin glargine n ( % ) / nmbrpy,arms;measures;p-interaction,arms
1939,a from baseline,measures;time/period,characteristic_name
1940,baselinec,measures;time/period,characteristic_level
1941,endpointc,measures;time/period,characteristic_level
1943,p valuea,measures;time/period,characteristic_level
1944,endpoint / baseline,measures;time/period,characteristic_name
1945,endpoint,measures;time/period,characteristic_level
1951,endpoint / baselinec,measures;time/period,characteristic_level
1953,vomiting,measures;outcomes;time/period,characteristic_level
1954,headache,measures;outcomes;time/period,characteristic_level
1955,nausea,measures;outcomes;time/period,characteristic_level
1956,dizziness,measures;outcomes;time/period,characteristic_level
1957,with an sfua,measures;outcomes;time/period,characteristic_level
1958,without an sfua,measures;outcomes;time/period,characteristic_level
1959,dyspepsia,measures;outcomes;time/period,characteristic_level
1960,diarrhea,measures;outcomes;time/period,characteristic_level
1961,baselineb,measures;outcomes;time/period,characteristic_level
1962,a from baselineb,measures;outcomes;time/period,characteristic_level
1963,decreased appetite,measures;outcomes;time/period,characteristic_level
1964,upper respiratory tract infection,measures;outcomes;time/period,characteristic_level
1965,nasopharyngitis,measures;outcomes;time/period,characteristic_level
1969,upper respiratory tract infection nmbr ( nmbr . nmbr ),measures;outcomes;time/period,characteristic_level
1979,intensified ( n 二 nmbr ),arms;measures,characteristic_level
1980,control ( n = nmbr ),arms;measures,arms
1982,intensified nmbr months ( n - nmbr ),arms;measures;time/period,characteristic_level
1983,control baseline ( n - nmbr ),arms;measures;time/period,characteristic_name
1984,intensified baseline ( n - nmbr ),arms;measures;time/period,characteristic_level
1985,p value,arms;measures;time/period,measures
1986,control nmbr months ( n - nmbr ),arms;measures;time/period,arms
1987,ipst ( n = nmbr ),arms;measures,characteristic_level
1988,"no ipst ( n = nmbr , nmbr )",arms;measures,characteristic_level
1990,p — value for interaction,arms;measures;p-interaction,measures
1991,losartan + lisinopril,arms;measures;p-interaction,arms
1992,n nmbr,arms;measures;p-interaction,characteristic_level
1993,[nmbr % cl],arms;measures;p-interaction,measures
1995,losartan + placebo,arms;measures;p-interaction,arms
1997,hazard ratio ( nmbr % cl ),arms;p-interaction,measures
1998,stent plus medical therapy,arms;p-interaction,characteristic_name
1999,medical therapy alone,arms;p-interaction,characteristic_name
2001,sex,characteristic_name;characteristic_level,characteristic_name
2003,m,characteristic_name;characteristic_level,characteristic_level
2004,australasia,characteristic_name;characteristic_level,characteristic_level
2005,latin america,characteristic_name;characteristic_level,characteristic_level
2007,f,characteristic_name;characteristic_level,characteristic_level
2009,europe,characteristic_name;characteristic_level,characteristic_level
2010,grouped region,characteristic_name;characteristic_level,characteristic_name
2011,united states,characteristic_name;characteristic_level,characteristic_level
2012,"baseline fev , ( l )",characteristic_name;characteristic_level,characteristic_name
2014,total ( n = nmbr ),measures;other,characteristic_level
2015,readmission ( n = nmbr ),measures;other,characteristic_level
2016,no readmission ( n = nmbr ),measures;other,characteristic_level
2018,no . of events / patients,measures;p-interaction,measures
2020,"weight - kg , median ( iqr )",characteristic_name;characteristic_level,characteristic_level
2021,"age - years , median ( iqr )",characteristic_name;characteristic_level,characteristic_level
2022,calcium antagonists,characteristic_name;characteristic_level,characteristic_level
2023,< nmbr . nmbr mg / mmol,characteristic_name;characteristic_level,characteristic_level
2024,> nmbr . nmbr %,characteristic_name;characteristic_level,characteristic_level
2025,"estimated glomerular filtration rate , n ( % )",characteristic_name;characteristic_level,characteristic_name
2026,sulfonylurea,characteristic_name;characteristic_level,characteristic_name
2027,"albumin / creatinine ratio , n ( % )",characteristic_name;characteristic_level,characteristic_name
2028,statins,characteristic_name;characteristic_level,characteristic_name
2029,"asian , n ( % )",characteristic_name;characteristic_level,characteristic_level
2030,"other , n ( % )",characteristic_name;characteristic_level,characteristic_level
2031,"prior myocardial infarction , n ( % )",characteristic_name;characteristic_level,characteristic_level
2032,"fasting serum glucose ( mg / dl ) , median ( iqr )",characteristic_name;characteristic_level,characteristic_level
2033,"weight > nmbr kg , n ( % )",characteristic_name;characteristic_level,characteristic_level
2034,nmbr . nmbr - < nmbr . nmbr %,characteristic_name;characteristic_level,characteristic_level
2035,insulin,characteristic_name;characteristic_level,characteristic_level
2036,< nmbr ml / min,characteristic_name;characteristic_level,characteristic_level
2037,"glycated hemoglobin , median ( iqr )",characteristic_name;characteristic_level,characteristic_name
2038,"age > nmbr years , n ( % )",characteristic_name;characteristic_level,characteristic_level
2039,"duration of diabetes , median ( iqr )",characteristic_name;characteristic_level,characteristic_level
2040,"body - mass index > nmbr , n ( % )",characteristic_name;characteristic_level,characteristic_name
2041,diuretics,characteristic_name;characteristic_level,characteristic_level
2042,"established atherosclerotic disease , n ( % )",characteristic_name;characteristic_level,characteristic_name
2043,race,characteristic_name;characteristic_level,characteristic_name
2044,thiazolidinediones,characteristic_name;characteristic_level,characteristic_name
2045,"body - mass index - kg / mnmbr , median ( iqr )",characteristic_name;characteristic_level,characteristic_name
2046,"hypertension , n ( % )",characteristic_name;characteristic_level,characteristic_level
2047,"glycated hemoglobin , n ( % )",characteristic_name;characteristic_level,characteristic_name
2048,< nmbr . nmbr %,characteristic_name;characteristic_level,characteristic_level
2049,nmbr . nmbr - < nmbr . nmbr mg / mmol,characteristic_name;characteristic_level,characteristic_level
2050,nmbr - < nmbr ml / min,characteristic_name;characteristic_level,characteristic_level
2051,angiotensin receptor blockers,characteristic_name;characteristic_level,characteristic_level
2052,"hispanic , n ( % )",characteristic_name;characteristic_level,characteristic_level
2053,"dyslipidemia , n ( % )",characteristic_name;characteristic_level,characteristic_level
2054,beta - blockers,characteristic_name;characteristic_level,characteristic_level
2055,"estimated glomerular filtration rate - ml / min , median ( iqr ) '",characteristic_name;characteristic_level,characteristic_name
2056,> nmbr . nmbr mg / mmol,characteristic_name;characteristic_level,characteristic_level
2057,> nmbr ml / min,characteristic_name;characteristic_level,characteristic_level
2059,"black , n ( % )",characteristic_name;characteristic_level,characteristic_level
2060,ace inhibitors,characteristic_name;characteristic_level,characteristic_level
2062,"white , n ( % )",characteristic_name;characteristic_level,characteristic_level
2063,"multiracial , n ( % )",characteristic_name;characteristic_level,characteristic_level
2065,"albumin / creatinine ratio - mg / mmol , median ( iqr )",characteristic_name;characteristic_level,characteristic_name
2066,"prior coronary revascularization , n ( % )",characteristic_name;characteristic_level,characteristic_level
2067,"no prior heart failure ( n = nmbr , nmbr )",characteristic_name;p-interaction,characteristic_level
2068,p - value,characteristic_name;p-interaction,measures
2069,"prior heart failure ( n = nmbr , nmbr )",characteristic_name;p-interaction,characteristic_level
2070,saxagliptin,arms;measures;p-interaction,arms
2075,fp / sal nmbr / nmbr pg ( n = nmbr ),arms;measures;p-interaction,arms
2076,sal nmbr pg ( n = nmbr ),arms;measures;p-interaction,characteristic_level
2078,ratio fp / sal : sal ( nmbr % ci ),arms;measures;p-interaction,measures
2079,russia / georgia ( n = nmbr ),arms;measures,characteristic_level
2080,americas ( n = nmbr ),arms;measures,characteristic_level
2082,spironolactone ( n = nmbr ),arms;measures,characteristic_level
2084,hr ( nmbr % ci ) p   value,arms;measures,measures
2085,russia / georgia ( n = nmbr ),measures;characteristic_level,characteristic_level
2086,americas ( n = nmbr ),measures;characteristic_level,characteristic_level
2087,"p , regional difference *",measures;characteristic_level,measures
2088,"p , treatment - by - region interaction",measures;characteristic_level,characteristic_name
2090,vorapaxar nmbr - y,arms;measures;p-interaction,arms
2092,placebo r %,arms;measures;p-interaction,arms
2094,vorapaxar ( n = nmbr . nmbr ),arms;measures,arms
2096,placebo ( n - nmbr . nmbr ),arms;measures,arms
2097,"egfr , nmbr ml / min / nmbr . nmbr mnmbr ( n = nmbr )",measures;characteristic_level,characteristic_level
2098,p,measures;characteristic_level,characteristic_level
2099,"egfr nmbr - nmbr ml / min / nmbr . nmbr mnmbr ( n = nmbr , nmbr )",measures;characteristic_level,characteristic_level
2100,"egfr . nmbr ml / min / nmbr . nmbr mnmbr ( n = nmbr , nmbr )",measures;characteristic_level,characteristic_level
2103,olmesartan ( n = nmbr ),arms;measures,characteristic_level
2104,hazard,measures;p-interaction,measures
2105,number,measures;p-interaction,characteristic_name
2107,nmbr % c . i .,measures;p-interaction,characteristic_level
2109,taci ( n = nmbr ),measures;characteristic_level,characteristic_level
2110,paci ( n = nmbr ),measures;characteristic_level,characteristic_level
2111,poci ( n = nmbr ),measures;characteristic_level,characteristic_level
2113,laci ( n = nmbr ),measures;characteristic_level,characteristic_level
2114,candesartan nmbr / nmbr,arms;measures,arms
2115,placebo nmbr / nmbr,arms;measures,arms
2117,"bw at nmbr weeks , kg +",outcomes;time/period,characteristic_level
2118,"baseline , mean ( sd )",outcomes;time/period,characteristic_level
2119,"fpg , mmol / lt",outcomes;time/period,characteristic_level
2120,patients with bw decrease of $ nmbr % in patients with baseline bmi of $ nmbr kg / mnmbr +,outcomes;time/period,characteristic_level
2121,"seated sbp at nmbr weeks , mmhg + * *",outcomes;time/period,characteristic_level
2122,responders of three - item end point at nmbr weeks *,outcomes;time/period,characteristic_level
2123,hbanmbrc at nmbr weeks *,outcomes;time/period,characteristic_level
2124,"change from baseline , adjusted mean ( nmbr % ci )",outcomes;time/period,measures
2125,"seated sbp at nmbr weeks , mmhg +",outcomes;time/period,characteristic_level
2126,"aspirin only ( n = nmbr , nmbr )",arms;measures,characteristic_level
2127,"aspirin i clopidogrel ( n = nmbr , nmbr )",arms;measures,characteristic_level
2129,western europe / australia,characteristic_name;characteristic_level,characteristic_level
2130,"assoc , with corrected congenital shunts",characteristic_name;characteristic_level,characteristic_level
2131,era and pdenmbr inhibitors,characteristic_name;characteristic_level,characteristic_level
2134,asia,characteristic_name;characteristic_level,characteristic_level
2135,pdenmbr inhibitor monotherapy,characteristic_name;characteristic_level,characteristic_level
2137,l / ll,characteristic_name;characteristic_level,characteristic_level
2138,no pah therapy,characteristic_name;characteristic_level,characteristic_name
2140,iii / iv,characteristic_name;characteristic_level,characteristic_level
2141,"ipah , hpah , hiv , drug or toxin induced",characteristic_name;characteristic_level,characteristic_level
2142,"assoc , with connective tissue disease",characteristic_name;characteristic_level,characteristic_level
2143,era monotherapy,characteristic_name;characteristic_level,characteristic_level
2146,nmbr years,characteristic_name;characteristic_level,characteristic_level
2148,selexipag,arms;p-interaction,characteristic_level
2150,bivalirudin ( n = nmbr ),arms;p-interaction,characteristic_level
2151,control ( n = nmbr ),arms;p-interaction,arms
2152,clopidogrel ( n = nmbr ) n / n ( % ),arms;measures,arms
2153,adjusted * or ( nmbr % ci ) p value,arms;measures,measures
2154,cangrelor ( n = nmbr ) n / n ( % ),arms;measures,arms
2155,unadjusted or ( nmbr % ci ) p value,arms;measures,measures
2156,women,characteristic_level;p-interaction,characteristic_level
2157,men,characteristic_level;p-interaction,characteristic_level
2158,p interaction ( rx arm * sex ),characteristic_level;p-interaction,characteristic_name
2162,aliskiren,arms;measures;p-interaction,arms
2163,cardiovascu lar subg roup,characteristic_level;outcomes,characteristic_level
2164,normoalbuminuria or microalbuminuria,characteristic_level;outcomes,characteristic_level
2165,macroalbuminuria,characteristic_level;outcomes,characteristic_level
2166,egfr < nmbr ml / min / nmbr - nmbr mnmbr,characteristic_level;outcomes,characteristic_level
2167,renal subgroup,characteristic_level;outcomes,characteristic_name
2168,egfr > nmbr ml / min / nmbr - nmbr mnmbr,characteristic_level;outcomes,characteristic_level
2169,pfor heterogeneity,measures;p-interaction,measures
2170,number of e,measures;p-interaction,characteristic_name
2172,vents / patients,measures;p-interaction,characteristic_level
2174,continued thienopyridine ( n = nmbr ),arms;measures,arms
2176,patients with diabetes mellitus,measures;characteristic_level,characteristic_level
2177,week nmbr mean ( se ),measures;time/period,measures
2178,from baseline ( nmbr % ci ),measures;time/period,measures
2179,baseline mean ( se ),measures;time/period,characteristic_level
2181,difference from placebo,measures;time/period,arms
2182,( nmbr % ci ),measures;time/period,measures
2183,adjusted mean change,measures;time/period,measures
2185,duration of assigned regimen before surgery,characteristic_name;characteristic_level,characteristic_name
2186,postoperative nsaid or glucocorticoid use,characteristic_name;characteristic_level,characteristic_name
2187,age,characteristic_name;characteristic_level,characteristic_name
2188,troponin nmbr at baseline,characteristic_name;characteristic_level,characteristic_name
2190,postoperative glucocorticoid use,characteristic_name;characteristic_level,characteristic_name
2191,previous statin use,characteristic_name;characteristic_level,characteristic_name
2192,surgical technique,characteristic_name;characteristic_level,characteristic_name
2193,procedure,characteristic_name;characteristic_level,characteristic_name
2194,clopidogrel plus aspirin ( n = nmbr ),arms;measures,arms
2196,aspirin ( n = nmbr ),arms;measures,characteristic_level
2198,nnmbr,measures;characteristic_level,arms
2199,< nmbr,measures;characteristic_level,characteristic_level
2200,on omt,measures;characteristic_level,characteristic_level
2201,off omt ( n = nmbr ),measures;characteristic_level,characteristic_level
2202,p value ( on vs off omt ),measures;characteristic_level,measures
2203,on omt ( n = nmbr ),measures;characteristic_level,characteristic_level
2204,off omt,measures;characteristic_level,characteristic_level
2205,baricitinib nmbr mg,arms;p-interaction,arms
2206,arr,arms;measures,characteristic_level
2207,simva,arms;measures,characteristic_level
2208,p - int,arms;measures,characteristic_level
2210,ez / simva,arms;measures,characteristic_level
2211,> nmbr % focal seizure frequency responders,measures;characteristic_level,characteristic_level
2212,minimal important change threshold ( improvement ) a,measures;characteristic_level,measures
2213,overall population,measures;characteristic_level,characteristic_level
2214,> nmbr,characteristic_level;measures,characteristic_level
2215,"age , mean ( sd ) , years",characteristic_level;measures,characteristic_level
2216,"baseline focal seizure frequency / nmbr days , median ( qnmbr , qnmbr )",characteristic_level;measures,characteristic_level
2217,nmbr - nmbr,characteristic_level;measures,characteristic_level
2218,"female , n ( % )",characteristic_level;measures,characteristic_level
2220,empagliflozin,arms;measures,arms
2221,p - value for interaction,arms;measures,measures
2223,hbanmbrc,characteristic_name;p-interaction,characteristic_name
2224,body mass index,characteristic_name;p-interaction,characteristic_name
2225,region,characteristic_name;p-interaction,characteristic_name
2226,egfr,characteristic_name;p-interaction,characteristic_level
2227,beta - blocker,characteristic_name;p-interaction,characteristic_level
2228,sulfonylurea,characteristic_name;p-interaction,characteristic_name
2229,urine albumin - to - creatinine ratio,characteristic_name;p-interaction,characteristic_name
2230,cardiovascular risk,characteristic_name;p-interaction,characteristic_name
2231,insulin,characteristic_name;p-interaction,characteristic_level
2232,race,characteristic_name;p-interaction,characteristic_name
2233,dpp - nmbr inhibitor,characteristic_name;p-interaction,characteristic_level
2234,ace inhibitor or arb,characteristic_name;p-interaction,characteristic_level
2235,acetylsalicylic acid,characteristic_name;p-interaction,characteristic_name
2236,calcium channel blocker,characteristic_name;p-interaction,characteristic_level
2237,statin or ezetimibe,characteristic_name;p-interaction,arms
2238,atrial fibrillation,characteristic_name;p-interaction,characteristic_level
2239,loop diuretic,characteristic_name;p-interaction,characteristic_level
2240,smoking status,characteristic_name;p-interaction,characteristic_name
2241,time since diagnosis of type nmbr diabetes,characteristic_name;p-interaction,characteristic_name
2242,diuretic,characteristic_name;p-interaction,characteristic_level
2243,sex,characteristic_name;p-interaction,characteristic_name
2244,metformin,characteristic_name;p-interaction,characteristic_level
2245,ethnicity,characteristic_name;p-interaction,characteristic_name
2246,blood pressure control,characteristic_name;p-interaction,characteristic_name
2247,age,characteristic_name;p-interaction,characteristic_name
2248,vitamin k antagonist,characteristic_name;p-interaction,characteristic_level
2249,heart failure,characteristic_name;p-interaction,characteristic_name
2250,previous stroke,characteristic_name;p-interaction,characteristic_level
2251,p - value,measures;time/period,measures
2252,mean change at week nmbr,measures;time/period,measures
2253,baseline ( n ),measures;time/period,characteristic_name
2254,mean = sd,measures;time/period,characteristic_level
2256,week nmbr,measures;time/period,characteristic_level
2257,mean difference = seb,measures;time/period,measures
2258,tofacitinib nmbr mg bid,arms;measures,arms
2264,without psoriasis ( zi = nmbr ),characteristic_level;p-interaction,characteristic_level
2265,p valuenmbr,characteristic_level;p-interaction,arms
2266,"without psoriasis ( zi = nmbr , nmbr )",characteristic_level;p-interaction,characteristic_level
2267,with psoriasis ( zi = nmbr ),characteristic_level;p-interaction,characteristic_level
2268,p value * nmbr,characteristic_level;p-interaction,measures
2272,atorvastatin ls means difference nmbr mg ( nmbr % ci ) a ( n = nmbr ),arms;measures,measures
2273,ls means difference ( nmbr % ci ) nmbr,arms;measures,measures
2274,interaction : treatment by psoriasis p valuenmbr,characteristic_level;p-interaction,characteristic_name
2275,patients without psoriasis ( n = nmbr ),characteristic_level;p-interaction,characteristic_level
2276,patients with psoriasis ( n = nmbr ),characteristic_level;p-interaction,characteristic_level
2278,canagliflozin ( n = nmbr ),arms;measures,characteristic_level
2279,"total ( n = nmbr , nmbr ) - -",arms;measures,characteristic_level
2280,< nmbr y ( n = nmbr ),measures;characteristic_level,characteristic_level
2282,> nmbr y ( n = nmbr ),measures;characteristic_level,characteristic_level
2284,of patients,measures;p-interaction,characteristic_level
2286,tiotropium group ( n = nmbr ),arms;measures,arms
2289,pfo closure,arms;measures;p-interaction,characteristic_level
2291,antiplatelet therapy,arms;measures;p-interaction,characteristic_level
2294,placebo no . of events / total no . ( % ),arms;measures;p-interaction,arms
2295,exenatide no . of events / total no . ( % ),arms;measures;p-interaction,arms
